NKI-AVL Publications 2008

438 in PubMed -- 25 Dissertations -- 27 Other publications

1. Impact Factor (2004): nvt-2.466¶
   Aaronson NK, Snyder C.  Using patient-reported outcomes in clinical practice: proceedings of an International Society of Quality of Life Research conference. Qual Life Res 2008; 17 (10): 1295
   PubMed link

2. Impact Factor (2004): 4.837¶
   Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JBAG, Schumacher TNM, Rosenberg SA, Restifo NP, Morgan RA.  T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. J Immunother 2008; 31 (1): 1-6.
   PubMed link

3. Impact Factor (2004): 6.068¶
   Abdallah AM, Savage ND, van Zon M, Wilson L, Vandenbroucke-Grauls CM, van der Wel NN, Ottenhoff TH, Bitter W.  The ESX-5 secretion system of Mycobacterium marinum modulates the macrophage response. J Immunol 2008; 181 (10): 7166-7175.
   PubMed link

4. Impact Factor (2004): 3.387¶
   Acquadro C, Conway K, Hareendran A, Aaronson N, European Regulatory Issues and Quality of Life Assessment (ERIQA) Group.  Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health 2008; 11 (3): 509-521.
   PubMed link

5. Impact Factor (2004): 4.290¶
   Al Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, Incrocci L, Lebesque JV.  Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72 (4): 980-988.
   PubMed link

6. Impact Factor (2004): 3.643¶
   Alvarez B, Stroeken PJ, Edel MJ, Roos E.  Integrin Cytoplasmic domain-Associated Protein-1 (ICAP-1) promotes migration of myoblasts and affects focal adhesions. J Cell Physiol 2008; 214 (2): 474-482.
   PubMed link

7. Impact Factor (2004): 11.092¶
   Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, et al.   Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Am J Hum Genet 2008; 82 (4): 937-948.
   PubMed link

8. Impact Factor (2004): 4.635¶
   Appels NMGM, Bolijn MJ, Chan K, Stephens TC, Hoctin-Boes G, Middleton M, Beijnen JH, de Bono JS, Harris AL, Schellens JHM.  Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br J Cancer 2008; 98 (12): 1951-1958.
   PubMed link

9. Impact Factor (2004): 1.429¶
   Baas P, Szczesna A, Albert I, Milanowski J, Juhasz E, Sztancsik Z, Von Pawel J, Oyama R, Burgers S.  Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J Thorac Oncol 2008; 3 (7): 745-750.
   PubMed link

10. Impact Factor (2004): 4.662¶
    Backer R, van Leeuwen F, Kraal G, den Haan JMM.  CD8-dendritic cells preferentially cross-present S. cerevisiae antigens. Eur J Immunol 2008; 38 (2): 370-380.
    PubMed link

11. Impact Factor (2004): 9.598¶
    Bakker AH, Hoppes R, Linnemann C, Toebes M, Rodenko B, Berkers CR, Hadrup SR, van Esch WJ, Heemskerk MH, Ovaa H, Schumacher TNM.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A 2008; 105 (10): 3825-3830.
    PubMed link

12. Impact Factor (2004): 6.440¶
    Baldanzi G, Cutrupi S, Chianale F, Gnocchi V, Rainero E, Porporato P, Filigheddu N, Van Blitterswijk WJ, Parolini O, Bussolino F, Sinigaglia F, Graziani A.  Diacylglycerol kinase-alpha phosphorylation by Src on Y335 is required for activation, membrane recruitment and Hgf-induced cell motility. Oncogene 2008; 27 (7): 942-956.
    PubMed link

13. Impact Factor (2004): 2.065¶
    Balm AJM, Smeele LE, Lohuis PJ.  Optimizing exposure of the posterolateral maxillary and pterygoid region: The lower cheek flap. Eur J Surg Oncol 2008; 34 699-703.
    PubMed link

14. Impact Factor (2004): 4.875¶
    Bartelink H.  Progress in radiotherapy for early breast cancer. Ann Oncol 2008; 19 Suppl 5 v117-v121
    PubMed link

15. Impact Factor (2004): nvt-28.638¶
    Bartelink H, Arriagada R.  Hypofractionation in radiotherapy for breast cancer [Comment]. Lancet 2008; 371 (9618): 1050-1052.
    PubMed link

16. Impact Factor (2004): nvt-4.074¶
    Begg A, van der Kogel A.  Clinical radiobiology in 2008 [editorial]. Radiother Oncol 2008; 86 (3): 295-299.
    PubMed link

17. Impact Factor (2004): 1.049¶
    Beijnen JH, Van Der Schoot SC, Nuijen B, Flesch FM, Gore A, Mirejovsky D, Lenaz L.  Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm 2008; 34 (10): 1130-1139.
    PubMed link

18. Impact Factor (2004): 4.290¶
    Belderbos JS, Kepka L, Spring Kong FM, Martel MK, Videtic GM, Jeremic B.  Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small-Cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008; 72 (2): 335-342.
    PubMed link

19. Impact Factor (2004): nvt¶
    Bernards R.  Cancer: Entangled pathways. Nature 2008; 455 (7212): 479-480.
    PubMed link

20. Impact Factor (2004): nvt¶
    Bernards R.  RNAi Delivers Insights into Liver Cancer. Cell 2008; 135 (5): 793-795.
    PubMed link

21. Impact Factor (2004): nvt-15.484¶
    Bernards R.  Reaction to American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2008; 26 (12): 2057-2058.
    PubMed link

22. Impact Factor (2004): nvt-29.887¶
    Berns A.  A tRNA with oncogenic capacity [Comment]. Cell 2008; 133 (1): 29-30.
    PubMed link

23. Impact Factor (2004): 2.986¶
    Bertaccini EJ, Lindahl E, Sixma T, Trudell JR.  Effect of cobratoxin binding on the normal mode vibration within acetylcholine binding protein. J Chem Inf Model 2008; 48 (4): 855-860.
    PubMed link

24. Impact Factor (2004): -¶
    Bex A.  Review: treatment of small cell carcinoma of the urinary bladder: can we learn from small cell lung cancer? Clin Adv Hematol Oncol 2008; 6 (5): 385-386.
    PubMed link

25. Impact Factor (2004): IP-2.217¶
    Bex A, de Vries R, Pos F, Kerst M, Horenblas S.  Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol 2008; Jul 8. [Epub ahead of print] in press
    PubMed link

26. Impact Factor (2004): 0.820¶
    Bex A, Haanen JB, Vyth-Dreese FA, Horenblas S, de Gast GC.  Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis. Urol Int 2008; 80 (4): 367-371.
    PubMed link

27. Impact Factor (2004): 4.555¶
    Bhatti P, Struewing JP, Alexander BH, Hauptmann M, Bowen L, Mateus-Pereira LH, Pineda MA, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Preston DL, Linet MS, Doody MM, Sigurdson AJ.  Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. Int J Cancer 2008; 122 (1): 177-182.
    PubMed link

28. Impact Factor (2004): 6.127¶
    Birks EJ, Latif N, Enesa K, Folkvang T, Luong le A, Sarathchandra P, Khan M, Ovaa H, Terracciano CM, Barton PJ, Yacoub MH, Evans PC.  Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 2008; 79 (3): 472-480.
    PubMed link

29. Impact Factor (2004): 2.217¶
    Bleeker MCG, Heideman DAM, Snijders PJF, Horenblas S, Dillner J, Meijer CJLM.  Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2008; Jul 8. [Epub ahead of print] in press
    PubMed link

30. Impact Factor (2004): 15.678¶
    Bleiker EMA, Hendriks JHCL, Otten JDM, Verbeek ALM, Van Der Ploeg HM.  Personality factors and breast cancer risk: A 13-year follow-up. J Natl Cancer Inst 2008; 100 (3): 213-218.
    PubMed link

31. Impact Factor (2004): geen¶
    Blussé van Oud-Alblas M, Fioole B, Jansen MC, van Duijnhoven FH, van Hillegersberg R, Rijken AM, van Coevorden F, Borel Rinkes IHM.  Radiofrequente ablatie van colorectale levermetastasen: resultaten vanaf de eerste toepassing in Nederland
    [Radiofrequency ablation of colorectal metastases to the liver: results since the first application in the Netherlands]. Ned Tijdschr Geneeskd 2008; 152 (15): 880-886.
    PubMed link

32. Impact Factor (2004): 5.423¶
    Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D, Schuuring E, Kluin P.   Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216 (2): 209-217.
    PubMed link

33. Impact Factor (2004): 2.007¶
    Borgemeester MC, van den Brekel MW, Van Tinteren H, Smeele LE, Pameijer FA, van Velthuysen ML, Balm AJ.  Ultrasound-guided aspiration cytology for the assessment of the clinically N0 neck: factors influencing its accuracy. Head Neck 2008; 30 (11): 1505-1513.
    PubMed link

34. Impact Factor (2004): 14.362¶
    Borst P, Sabatini R.  Base J: discovery, biosynthesis, and possible functions. Annu Rev Microbiol 2008; 62 235-251.
    PubMed link

35. Impact Factor (2004): nvt-9.598¶
    Borst P.  Mega-dose vitamin C as therapy for human cancer? [Letter]. Proc Natl Acad Sci U S A 2008; 105 (48): E95
    PubMed link

36. Impact Factor (2004): 3.314¶
    Borst P, Van De Wetering K, Schlingemann R.  Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery? Cell Cycle  2008; 7 (11): 1575-1579.
    PubMed link

37. Impact Factor (2004): 3.314¶
    Borst P, Rottenberg S, Jonkers J.  How do real tumors become resistant to cisplatin? Cell Cycle 2008; 7 (10): 1353-1359.
    PubMed link

38. Impact Factor (2004): 7.672¶
    Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TN, Haanen JB, van der Burg SH, Melief CJ, Offringa R.  Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008; 68 (20): 8446-8455.
    PubMed link

39. Impact Factor (2004): IP-5.806¶
    Bosma I, Reijneveld JC, Douw L, Vos MJ, Postma TJ, Aaronson NK, Muller M, Vandertop WP, Slotman BJ, Taphoorn MJ, Heimans JJ, Klein M.  Health-related quality of life of long-term high-grade glioma survivors. Neuro Oncol 2008; Jul 10. [Epub ahead of print] in press
    PubMed link

40. Impact Factor (2004): 4.876¶
    Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH.  In reply. Oncologist 2008; 13 (6): 736-737.
    PubMed link

41. Impact Factor (2004): 4.876¶
    Boss DS, Valdés Olmos RA, Sinaasappel M, Beijnen JH.  Application of PET/CT in the development of novel anti-cancer drugs:a review. Oncologist 2008; 13 25-38.
    PubMed link

42. Impact Factor (2004): 2.065¶
    Bossema E, Stiggelbout A, Baas-Thijssen M, van de Velde C, Marijnen C.  Patients' preferences for low rectal cancer surgery. Eur J Surg Oncol 2008; 34 (1): 42-48.
    PubMed link

43. Impact Factor (2004): -¶
    Boutsma E, Noback S, van Lohuizen M.  The Polycomb protein and E3 ubiquitin ligase Ring1B harbors an IRES in its highly conserved 5' UTR. PLoS ONE 2008; 3 (6): e2322
    PubMed link

44. Impact Factor (2004): 3.314¶
    Bouwman P, Jonkers J.  Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. Cell Cycle 2008; 7 (17): 2647-2653.
    PubMed link

45. Impact Factor (2004): 7.531¶
    Braam SR, Zeinstra L, Litjens S, Ward-van Oostwaard D, van den Brink S, van Laake L, Lebrin F, Kats P, Hochstenbach R, Passier R, Sonnenberg A, Mummery CL.  Recombinant Vitronectin is a Functionally Defined Substrate that Supports Human Embryonic Stem Cell Self Renewal via {alpha}V{beta}5 Integrin. Stem Cells 2008; 26 (9): 2257-2265.
    PubMed link

46. Impact Factor (2004): 1.792¶
    Bramsen I, van der Linden MH, Eskens FJ, Bijvank EM, van Groeningen CJ, Kaufman HJ, Aaronson NK.  Evaluation of a face-to-face psychosocial screening intervention for cancer patients: Acceptance and effects on quality of life. Patient Educ Couns 2008; 70 (1): 61-68.
    PubMed link

47. Impact Factor (2004): 4.453¶
    Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, van 't Veer LJ.  The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat 2008; 107 (2): 243-248.
    PubMed link

48. Impact Factor (2004): -¶
    Brouwers EE, Huitema AD, Beijnen JH, Schellens JH.  Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008; 8 7 (10pp)
    PubMed link

49. Impact Factor (2004): 2.357¶
    Brouwers EE, Huitema AD, Schellens JH, Beijnen JH.  The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry. Anticancer Drugs 2008; 19 (6): 621-630.
    PubMed link

50. Impact Factor (2004): 2.867¶
    Brouwers EEM, Tibben MM, Pluim D, Rosing H, Boot H, Cats A, Schellens JHM, Beijnen JH.  Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Anal Bioanal Chem 2008; 391 (2): 577-585.
    PubMed link

51. Impact Factor (2004): 10.896¶
    Brouwers EEM, Tibben M, Rosing H, Schellen JHM, Beijnen JH.  The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. Mass Spectrom Rev 2008; 27 (2): 67-100.
    PubMed link

52. Impact Factor (2004): 1.435¶
    Buitelaar D, Huitink J, Oldenburg H, Rutgers E, Schutte P, Van Tinteren H.  Field block: An additional technique of potential value for breast surgery under general anaesthesia [6]. Eur J Anaesthesiol 2008; 25 (3): 253-255.
    PubMed link

53. Impact Factor (2004): 5.349¶
    Burgers JA, Kunst PW, Koolen MG, Willems LN, Burgers JS, van den Heuvel M.  Pleural drainage and pleurodesis; implementation of the Dutch guidelines in four hospitals. Eur Respir J 2008; 32 (5): 1321-1327.
    PubMed link

54. Impact Factor (2004): 4.454¶
    Capelle LG, de Vries AC, Looman CW, Casparie MK, Boot H, Meijer GA, Kuipers EJ.  Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44( (16): 2470-2476.
    PubMed link

55. Impact Factor (2004): 3.168¶
    Ceelen M, van Weissenbruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA.  Growth and development of children born after in vitro fertilization. Fertil Steril 2008; 90 (5): 1662-1673.
    PubMed link

56. Impact Factor (2004): 5.493¶
    Ceelen M, van Weissenbruch MM, Vermeiden JPW, van Leeuwen FE, Delemarre-Van De Waal HA.  Cardiometabolic differences in children born after in vitro fertilization: Follow-up study. J Clin Endocrinol Metab 2008; 93 (5): 1682-1688.
    PubMed link

57. Impact Factor (2004): 3.543¶
    Ceelen M, van Weissenbruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA.  Pubertal development in children and adolescents born after IVF and spontaneous conception. Hum Reprod 2008; 23 (12): 2791-2798.
    PubMed link

58. Impact Factor (2004): 4.555¶
    Claes A, Gambarota G, Hamans B, van Tellingen O, Wesseling P, Maass C, Heerschap A, Leenders W.   Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int J Cancer 2008; 122 (1): 1981-1986.
    PubMed link

59. Impact Factor (2004): 2.709¶
    Cleton-Jansen AM, van Eijk R, Lombaerts M, Schmidt MK, van't Veer LJ, Philippo K, Zimmerman RME, Peterse JL, Smit VTBH, van Wezel T, Cornelisse CJ.  ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: Absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. BMC Cancer 2008; 8 105 (12pp)
    PubMed link

60. Impact Factor (2004): 6.068¶
    Coccoris M, Swart E, De Witte MA, van Heijst JW, Haanen JBAG, Schepers K, Schumacher TNM.  Long-term functionality of TCR-transduced T cells in vivo. J Immunol 2008; 180 (10): 6536-6543.
    PubMed link

61. Impact Factor (2004): 2.620¶
    Cohen SX, Ben Jelloul M, Long F, Vagin A, Knipscheer P, Lebbink J, Sixma TK, Lamzin VS, Murshudov GN, Perrakis A.  ARP/wARP and molecular replacement: the next generation. Acta Crystallogr D Biol Crystallogr 2008; 64 (Pt 1): 49-60.
    PubMed link

62. Impact Factor (2004): 2.935¶
    Damen CW, Rosing H, Tibben MM, van Maanen MJ, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH.  A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 868 (1-2): 102-109.
    PubMed link

63. Impact Factor (2004): 2.761¶
    Damen CW, Rosing H, Schellens JHM, Beijnen JH.  Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. J Pharm Biomed Anal 2008; 46 449-455.
    PubMed link

64. Impact Factor (2004): 5.516¶
    de Boer JP, Hiddink RF, Raderer M, Antonini N, Aleman BMP, Boot H, de Jong D.  Dissemination patterns in non-gastric MALT lymphoma. Haematologica 2008; 93 (2): 201-206.
    PubMed link

65. Impact Factor (2004): 6.250¶
    De Bruin EC, Van DeVelde CJH, Van Krieken JHJM, Marijnen CAM, Medema JP.  Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients. Clin Cancer Res 2008; 14 (4): 1073-1079.
    PubMed link

66. Impact Factor (2004): 10.896¶
    De Bruin ML, Huisbrink J, Hauptmann M, Kuenen MA, Ouwens GM, 't Veer MB, Aleman BM, van Leeuwen FE.  Treatment-related risk factors for premature menopause following Hodgkin's lymphoma. Blood 2008; 111 (1): 101-108.
    PubMed link

67. Impact Factor (2004): 25.547¶
    de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbe E, Casparie MK, van Leeuwen FE.  Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008; 300 (17): 2030-2035.
    PubMed link

68. Impact Factor (2004): 13.156¶
    De Keersmaecker K, Rocnik JL, Bernad R, Lee BH, Leeman D, Gielen O, Verachtert H, Folens C, Munck S, Marynen P, Fornerod M, Gilliland DG, Cools J.  Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. Mol Cell 2008; 31 (1): 134-142.
    PubMed link

69. Impact Factor (2004): 4.454¶
    de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN.  Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008; 44 (4): 551-556.
    PubMed link

70. Impact Factor (2004): geen¶
    de Mulder PHM, Haanen JBAG, Sleijfer S, Kruit WHJ, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJM, Osanto S, Jansen RL, Mulders PFA.  [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]
    Angiogeneseremmers voor de systemische behandeling van gemetastaseerd niercelcarcinoom: sunitinib, sorafenib, bevacizumab en temsirolimus. Ned Tijdschr Geneeskd 2008; 152 (7): 371-375.
    PubMed link

71. Impact Factor (2004): IP-4.074¶
    De Ruysscher D, Dehing C, Yu S, Wanders R, Ollers M, Dingemans AM, Bootsma G, Hochstenbag M, Geraedts W, Pitz C, Simons J, Boersma L, Borger J, Dekker A, Lambin P.  Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol 2008; Nov 12. [Epub ahead of print] in press
    PubMed link

72. Impact Factor (2004): 3.728¶
    de Visser KE.  Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both? Cancer Immunol Immunother 2008; 57 (10): 1531-1539.
    PubMed link

73. Impact Factor (2004): -¶
    de Vreeze RS, Koops W, Haas RL, van Coevorden F.  An unusual case of hemosiderotic fibrohistiocytic lipomatous lesion: correlation of MRI and pathologic findings. Sarcoma 2008; 2008 893918
    PubMed link

74. Impact Factor (2004): 4.290¶
    de Vreeze RSA, de Jong D, Haas RL, Stewart F, van Coevorden F.  Effectiveness of Radiotherapy in Myxoid Sarcomas is Associated with a Dense Vascular Pattern. Int J Radiat Oncol Biol Phys 2008; 72 (5): 1480-1487.
    PubMed link

75. Impact Factor (2004): 8.721¶
    de Wit E, Braunschweig U, Greil F, Bussemaker HJ, van Steensel B.  Global chromatin domain organization of the Drosophila genome. PLoS Genet 2008; 4 (3): e1000045
    PubMed link

76. Impact Factor (2004): 6.068¶
    De Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS, Van Tinteren H, Mesman EM, Song JY, Schumacher TNM.  TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol 2008; 181 (4): 2563-2571.
    PubMed link

77. Impact Factor (2004): 6.068¶
    De Witte MA, Jorritsma A, Swart E, Straathof KC, de Punder K, Haanen JB, Rooney CM, Schumacher TN.  An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol 2008; 180 (9): 6365-6373.
    PubMed link

78. Impact Factor (2004): 6.068¶
    De Witte MA, Jorritsma A, Kaiser A, van den Boom MD, Dokter M, Bendle GM, Haanen JBAG, Schumacher TNM.  Requirements for effective antitumor responses of TCR transduced T cells. J Immunol 2008; 181 (7): 5128-5136.
    PubMed link

79. Impact Factor (2004): 4.800¶
    de Wolf C, Jansen R, Yamaguchi H, de Haas M, Van De Wetering K, Wijnholds J, Beijnen J, Borst P.  Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther 2008; 7 (9): 3092-3102.
    PubMed link

80. Impact Factor (2004): 3.917¶
    DeBree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD.  Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: A clinical and pharmacokinetic study. Ann Surg Oncol 2008; 15 (4): 1183-1192.
    PubMed link

81. Impact Factor (2004): 4.454¶
    den Dulk M, Krijnen P, Marijnen CA, Rutten HJ, van de Poll-Franse LV, Putter H, Meershoek-Klein Kranenbarg E, Jansen-Landheer ML, Coebergh JW, Van de Velde CJ.  Improved overall survival for patients with rectal cancer since 1990: The effects of TME surgery and pre-operative radiotherapy. Eur J Cancer 2008; 44( (12): 1710-1716.
    PubMed link

82. Impact Factor (2004): 2.935¶
    Dorlo TPC, Hillebrand MJX, Rosing H, Eggelte TA, de Vries PJ, Beijnen JH.  Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2008; 865 (1-2): 55-62.
    PubMed link

83. Impact Factor (2004): 2.589¶
    Douma KF, Aaronson NK, Vasen HF, Bleiker EM.  Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. Psychooncology 2008; 17 (8): 737-745.
    PubMed link

84. 
    Duursma AM, Kedde M, Schrier M, le Sage C, Agami R.  miR-148 targets human DNMT3b protein coding region. RNA 2008; 14 (5): 872-877.
    PubMed link

85. Impact Factor (2004): 7.672¶
    Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J.  Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68 (22): 9221-9230.
    PubMed link

86. Impact Factor (2004): 2.568¶
    Ekhart C, Kerst JM, Rodenhuis S, Beijnen JH, Huitema ADR.  Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. Cancer Chemother Pharmacol 2008; in press
    PubMed link

87. Impact Factor (2004): 5.775¶
    Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.  Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008; 18 (6): 515-523.
    PubMed link

88. Impact Factor (2004): 5.775¶
    Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.  Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008; 18 (11): 1009-1015.
    PubMed link

89. Impact Factor (2004): 2.568¶
    Ekhart C, Rodenhuis S, Beijnen JH, Huitema ADR.  Carbamazepine induces bioactivation of cyclophosphamide and thiotepa. Cancer Chemother Pharmacol 2008; 63 (3): 543-547.
    PubMed link

90. Impact Factor (2004): 6.236¶
    Elkon R, Agami R.  Removal of AU bias from microarray mRNA expression data enhances computational identification of active microRNAs. PLoS Comput Biol 2008; 4 (10): e1000189
    PubMed link

91. Impact Factor (2004): 6.028¶
    Engelsma D, Valle N, Fish A, Salome N, Almendral JM, Fornerod M.  A supraphysiological nuclear export signal is required for parvovirus nuclear export. Mol Biol Cell 2008; 19 (6): 2544-2552.
    PubMed link

92. Impact Factor (2004): 3.907¶
    Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y.  Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 2008; 36 (6): 995-1002.
    PubMed link

93. Impact Factor (2004): 4.635¶
    Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R.  PRAME expression and clinical outcome of breast cancer. Br J Cancer 2008; 99 (3): 398-403.
    PubMed link

94. Impact Factor (2004): 6.250¶
    Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J.  Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14 (12): 3916-3925.
    PubMed link

95. Impact Factor (2004): 4.290¶
    Fitton I, Steenbakkers RJ, Gilhuijs K, Duppen JC, Nowak PJ, van Herk M, Rasch CR.  Impact of Anatomical Location on Value of CT-PET Co-Registration for Delineation of Lung Tumors. Int J Radiat Oncol Biol Phys 2008; 70 1403-1407.
    PubMed link

96. Impact Factor (2004): 6.440¶
    Foijer F, Simonis M, van Vliet M, Wessels L, Kerkhoven R, Sorger PK, Te Riele H.  Oncogenic pathways impinging on the G(2)-restriction point. Oncogene 2008; 27 1142-1154.
    PubMed link

97. Impact Factor (2004): 7.450¶
    Fornerod M, Clarke PR.  To the centre of the volcano. Workshop on the mechanisms of nucleocytoplasmic transport. EMBO Rep 2008; 9 (5): 419-424.
    PubMed link

98. Impact Factor (2004): -¶
    Frankfort SV, van Campen JP, Tulner LR, Beijnen JH.  Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS). Curr Clin Pharmacol 2008; 3 (3): 144-154.
    PubMed link

99. Impact Factor (2004): -¶
    Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.  Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol 2008; 3 (2): 123-131.
    PubMed link

100. Impact Factor (2004): 11.085¶
     Frederiks F, Tzouros M, Oudgenoeg G, van Welsem T, Fornerod M, Krijgsveld J, van Leeuwen F.  Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. Nat Struct Mol Biol 2008; 15 (6): 550-557.
     PubMed link

101. 
     Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, Jassem E, Niklinski J, Muley T, Van Zandwijk N, Smit EF, Beebe K, Neckers L, Yistra B, Giaccone G.  Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS ONE 2008; 3 (3): e0001722
     PubMed link

102. Impact Factor (2004): 4.635¶
     Gambarota G, Leenders W, Maass C, Wesseling P, van der Kogel B, van Tellingen O, Heerschap A.  Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. Br J Cancer 2008; 98 (11): 1784-1789.
     PubMed link

103. 
     Gast MCW, Engwegen JY, Schellens JHM, Beijnen JH.  Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. BMC Med Genomics 2008; 1 4 (12 pp)
     PubMed link

104. 
     Gast MCW, Van Tinteren H, Bontenbal M, van Hoesel RQ, Nooij MA, Rodenhuis S, Span PN, Tjan-Heijnen VC, de Vries EG, Harris N, Twisk JW, Schellens JH, Beijnen JH.  Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer 2008; 8 389
     PubMed link

105. Impact Factor (2004): 4.101¶
     Gedik GK, Hoefnagel CA, Bais E, Valde?s Olmos.  131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008; 35 (4): 725-733.
     PubMed link

106. Impact Factor (2004): 10.169¶
     Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ.  Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol 2008; 7 (6): 548-560.
     PubMed link

107. Impact Factor (2004): 4.074¶
     Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Der Maazen RV, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P.  The conundrum of hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 2008; 88 (2): 202-210.
     PubMed link

108. Impact Factor (2004): 7.490¶
     Godsave SF, Wille H, Kujala P, Latawiec D, Dearmond SJ, Serban A, Prusiner SB, Peters PJ.  Cryo-Immunogold Electron Microscopy for Prions: Toward Identification of a Conversion Site. J Neurosci 2008; 28 (47): 12489-12499.
     PubMed link

109. Impact Factor (2004): 4.714¶
     Goessling W, North TE, Lord AM, Ceol C, Lee S, Weidinger G, Bourque C, Strijbosch R, Haramis AP, Puder M, Clevers H, Moon RT, Zon LI.  APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. Dev Biol 2008; 320 (1): 161-174.
     PubMed link

110. Impact Factor (2004): 1.856¶
     Gremmer R, Schroder ML, Ten Bokkel Huinink WW, Brandsma D, Boogerd W.  Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy. J Neurooncol 2008; 90 (3): 335-339.
     PubMed link

111. Impact Factor (2004): 4.453¶
     Gronwald J, Pijpe A, Byrski T, Huzarski T, Stawicka M, Cybulski C, van Leeuwen F, ski J, Narod SA.  Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat 2008; 112 (3): 581-584.
     PubMed link

112. Impact Factor (2004): 28.751¶
     Guelen L, Pagie L, Brasset E, Meuleman W, Faza MB, Talhout W, Eussen BH, de Klein A, Wessels L, de Laat W, van Steensel B.  Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature 2008; 453 (7197): 948-951.
     PubMed link

113. Impact Factor (2004): 3.554¶
     Gundy CM, Aaronson NK.  The influence of proxy perspective on patient-proxy agreement in the evaluation of health-related quality of life: An empirical study. Med Care 2008; 46 (2): 209-216.
     PubMed link

114. Impact Factor (2004): 3.478¶
     Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH, de Jong D, Eldering E, van Oers MH, Mellink CH, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS.  Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 2008; 10 (5): 442-451.
     PubMed link

115. Impact Factor (2004): 0.575¶
     Hage JJ.  On the origin and evolution of the Roeder knot and loop: a geometrical review. Surg Laparoscop Endosc Percutan Tech 2008; 18 1-7.
     PubMed link

116. Impact Factor (2004): 1.778¶
     Hage JJ.  Heraklas on knots: Sixteen surgical nooses and knots from the first century A.D. World J Surg 2008; 32 (4): 648-655.
     PubMed link

117. Impact Factor (2004): 4.875¶
     Hage JJ, Woerdeman LA.  The design of the lateral thoracodorsal flap. Ann Plast Surg 2008; 61 (3): 302-305.
     PubMed link

118. Impact Factor (2004): 6.924¶
     Hagenbeek TJ, Spits H.  T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 2008; 22 (3): 608-619.
     PubMed link

119. Impact Factor (2004): 4.180¶
     Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, van't Veer L, Piccart M, Bontempi G, Sotiriou C.  Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 2008; 9 394
     PubMed link

120. Impact Factor (2004): 15.484¶
     Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grutzmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Muller V, Milde-Langosch K, Nahrig J, Foekens J, Maier S, Schmitt M, Lesche R.  Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients. J Clin Oncol 2008; 26 (31): 5036-5042.
     PubMed link

121. Impact Factor (2004): 3.907¶
     Harmsen S, Koster AS, Beijnen JH, Schellens JHM, Meijerman I.  Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction.  Drug Metab Dispos 2008; 36 (6): 1166-1171.
     PubMed link

122. Impact Factor (2004): 2.072¶
     Hartog H, van der Graaf WTA, Wesseling J, van der Veer E, Boezen HM.  Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples. Clin Biochem 2008; 41 (7-8): 636-639.
     PubMed link

123. Impact Factor (2004): 9.598¶
     Hava DL, van der Wel N, Cohen N, Dascher CC, Houben D, Leon L, Agarwal S, Sugita M, van Zon M, Kent SC, Shams H, Peters PJ, Brenner MB.  Evasion of peptide, but not lipid antigen presentation, through pathogen-induced dendritic cell maturation. Proc Natl Acad Sci U S A 2008; 105 (32): 11281-11286.
     PubMed link

124. Impact Factor (2004): 7.293¶
     Hawkins TA, Haramis AP, Etard C, Prodromou C, Vaughan CK, Ashworth R, Ray S, Behra M, Holder N, Talbot WS, Pearl LH, hle U, Wilson SW.  The ATPase-dependent chaperoning activity of Hsp90a regulates thick filament formation and integration during skeletal muscle myofibrillogenesis. Development 2008; 135 (6): 1147-1156.
     PubMed link

125. Impact Factor (2004): 4.181¶
     Heerema-McKenney A, Wijnaendts LC, Pulliam JF, Lopez-Terrada D, McKenney JK, Zhu S, Montgomery K, Mitchell J, Marinelli RJ, Hart AA, Van De Rijn M, Linn SC.  Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Am J Surg Pathol 2008; 32 (10): 1513-1522.
     PubMed link

126. Impact Factor (2004): 15.484¶
     Helgason HH, Mallo HA, Droogendijk H, Haanen JG, van der Veldt AA, van den Eertwegh AJ, Boven E.  Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol 2008; 26 (1): 152-154.
     PubMed link

127. Impact Factor (2004): 6.383¶
     Hendriksen J, Jansen M, Brown CM, van der Velde H, van Ham M, Galjart N, Offerhaus GJ, Fagotto F, Fornerod M.  Plasma membrane recruitment of dephosphorylated beta-catenin upon activation of the Wnt pathway. J Cell Sci 2008; 121 (Pt 11): 1793-1802.
     PubMed link

128. Impact Factor (2004): 1.070¶
     Hendry JH, Akahoshi M, Wang LS, Lipshultz SE, Stewart FA, Trott KR.  Radiation-induced cardiovascular injury. Radiat Environ Biophys 2008; 47 189-193.
     PubMed link

129. Impact Factor (2004): -¶
     Hennink S, Wouters MW, Klomp HM, Baas P.  Necrotizing pneumonitis caused by postoperative pulmonary torsion. Interact Cardiovasc Thorac Surg 2008; 7 (1): 144-145.
     PubMed link

130. Impact Factor (2004): 8.662¶
     Herold S, Hock A, Herkert B, Berns K, Mullenders J, Beijersbergen R, Bernards R, Eilers M.  Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO J 2008; 27 (21): 2851-2861.
     PubMed link

131. Impact Factor (2004): 4.632¶
     Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK.  Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study. Cancer 2008; 113 (3): 628-637.
     PubMed link

132. Impact Factor (2004): 1.801¶
     Hilgers FJ, Soolsma J, Ackerstaff AH, Balm FJ, Tan IB, van den Brekel MW.  A Thin Tracheal Silicone Washer to Solve Periprosthetic Leakage in Laryngectomies: Direct Results and Long-Term Clinical Effects. Laryngoscope 2008; 118(4):640-5 (4): 640-645.
     PubMed link

133. Impact Factor (2004): nvt-2.007¶
     Hilgers FJ, van den Brekel MW, Van Tinteren H.  Views on Acton et al's "Investigation of tracheoesophageal voice prosthesis leakage patterns: Patient's self-report versus clinician's confirmation". Head Neck 2008; 30 (12): 1660-1661.
     PubMed link

134. Impact Factor (2004): 4.454¶
     Ho VKY, van der Heiden-van der Loo, Rutgers EJT, van Diest PJ, Hobbelink MGG, Tjan-Heijnen VCG, Dirx MJM, Reedijk AMJ, van Dijck JAAM, Poll-Franse LV, Schaapveld M, Peeters PHM.  Implementation of sentinel node biopsy in breast cancer patients in the Netherlands. Eur J Cancer 2008; 44 (5): 683-691.
     PubMed link

135. Impact Factor (2004): 1.186¶
     Hodge JW, Guha C, Neefjes J, Gulley JL.  Synergizing Radiation Therapy and Immunotherapy for Curing Incurable Cancers
     Opportunities and Challenges. Oncology 2008; 22 (9): 1064-1070.
     PubMed link

136. Impact Factor (2004): 4.101¶
     Hoebers FJ, Kartachova M, de Bois J, Van Den Brekel MWM, Van Tinteren H, van Herk M, Rasch CR, Valdes Olmos RA, Verheij M.  (99m)Tc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 2008; 35 (3): 509-518.
     PubMed link

137. Impact Factor (2004): 2.568¶
     Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH, Stalpers LJ, Bartelink H, Begg AC.  Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol 2008; 61 1075-1081.
     PubMed link

138. Impact Factor (2004): 4.101¶
     Hoebers FJP, Kartachova M, de Bois J, Van Den Brekel MWM, Van Tinteren H, van Herk M, Rasch CRN, Valde?s Olmos, Verheij M.  99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 2008; 35 (3): 509-518.
     PubMed link

139. Impact Factor (2004): 3.791¶
     Hofmann M, Stoss O, Shi D, Büttner R, Van De Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52 (7): 797-805.
     PubMed link

140. Impact Factor (2004): 6.273¶
     Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, de Wind N, Hoogerbrugge N, Hogervorst FBL, IARC Unclassified Genetic Variants Working Group.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat 2008; 29 (11): 1292-1303.
     PubMed link

141. Impact Factor (2004): 5.423¶
     Holm C, Kok M, Michalides R, Fles R, Koornstra R, Wesseling J, Hauptmann M, Neefjes J, Peterse J, Stal O, Landberg G, Linn S.  Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 2008; 217 (3): 372-379.
     PubMed link

142. Impact Factor (2004): 4.453¶
     Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE.  Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat 2008; 112 (1): 99-108.
     PubMed link

143. Impact Factor (2004): 15.484¶
     Hooning MJ, Aleman BM, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, Stovall M, van Leeuwen FE.   Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer. J Clin Oncol 2008; 26 (34): 5561-5568.
     PubMed link

144. Impact Factor (2004): 1.372¶
     Hoopman R, Terwee CB, Muller MJ, Ory FG, Aaronson NK.  Methodological challenges in quality of life research among Turkish and Moroccan ethnic minority cancer patients: translation, recruitment and ethical issues. Ethn Health 2008; 1-16.
     PubMed link

145. Impact Factor (2004): 2.565¶
     Hoopman R, Terwee CB, Aaronson NK.  Translated COOP/WONCA charts found appropriate for use among Turkish and Moroccan ethnic minority cancer patients. J Clin Epidemiol 2008; 61 (10): 1036-1048.
     PubMed link

146. Impact Factor (2004): nvt-5.634¶
     Horenblas S.  Editorial Comment on: Peniscopically Controlled CO2 Laser Excision for Conservative Treatment of in Situ and T1 Penile Carcinoma: Report on 224 Patients. Eur Urol 2008; 54 (4): 883-884.
     PubMed link

147. Impact Factor (2004): nvt-5.634¶
     Horenblas S.  Editorial comment on: Diabetes mellitus: does it impair urinary continence after radical cystoprostatectomy and ileal orthotopic bladder substitution? Eur Urol 2008; 53 1046-1047.
     PubMed link

148. Impact Factor (2004): 15.484¶
     Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, van't Veer LJ, de Jong D.  Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008; 26 (27): 4435-4441.
     PubMed link

149. Impact Factor (2004): 4.290¶
     Hoving S, Heeneman S, Gijbels MJ, te Poele JA, Russell NS, Daemen MJ, Stewart FA.  Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(-/-) mice. Int J Radiat Oncol Biol Phys 2008; 71 (3): 848-857.
     PubMed link

150. Impact Factor (2004): 15.612¶
     Hömig-Hölzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Müller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, Zimber-Strobl U.  Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-?B pathway and promotes lymphomagenesis. J Exp Med 2008; 205 (6): 1317-1329.
     PubMed link

151. Impact Factor (2004): 17.623¶
     Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E, Agami R.  The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10 202-210.
     PubMed link

152. Impact Factor (2004): IP-2.217¶
     Hughes B, Leijte J, Shabbir M, Watkin N, Horenblas S.  Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer. World J Urol 2008; in press
     PubMed link

153. Impact Factor (2004): -¶
     Huijbers EJ, Baars JW, Schutte PF, Schellens JH, Beijnen J.  Propofol extravasation in a breast cancer patient. J Oncol Pharm Pract 2008; 14 (4): 195-198.
     PubMed link

154. Impact Factor (2004): 31.921¶
     Iden S, Collard JG.  Crosstalk between small GTPases and polarity proteins in cell polarization. Nat Rev Mol Cell Biol 2008; 9 (11): 846-859.
     PubMed link

155. Impact Factor (2004): 2.279¶
     Jansen APD, van Hout HPJ, Nijpels G, van Marwijk HWJ, Gundy C, De Vet HCW, Stalman WAB.  Self-reports on the IQCODE in older adults: A psychometric evaluation. J Geriatr Psychiatry Neurol 2008; 21 (2): 83-92.
     PubMed link

156. Impact Factor (2004): 1.696¶
     Jansen M, Harting J, Ebben N, Kroon B, Stappers J, Van Engelshoven E, de Vries N.  The concept of sustainability and the use of outcome indicators. A case study to continue a successful health counselling intervention. Fam Pract  2008; 25 Suppl 1 i32-i37
     PubMed link

157. Impact Factor (2004): 2.065¶
     Jansen MC, van Wanrooy S, van Hillegersberg R, Rijken AM, van Coevorden F, Prevoo W, van Gulik TM.  Assessment of systemic inflammatory response (SIR) in patients undergoing radiofrequency ablation or partial liver resection for liver tumors. Eur J Surg Oncol 2008; 34 662-667.
     PubMed link

158. Impact Factor (2004): 2.466¶
     Jayasekara H, Rajapaksa LC, Aaronson NK.  Quality of life in cancer patients in South Asia: psychometric properties of the Sinhala version of the EORTC QLQ-C30 in cancer patients with heterogeneous diagnoses. Qual Life Res 2008; 17 (5): 783-791.
     PubMed link

159. Impact Factor (2004): 1.597¶
     Ji BT, Blair A, Shu XO, Chow WH, Hauptmann M, Dosemeci M, Yang G, Lubin J, Gao YT, Rothman N, Zheng W.  Occupation and breast cancer risk among Shanghai women in a population-based cohort study. Am J Ind Med 2008; 51 (2): 100-110.
     PubMed link

160. Impact Factor (2004): nvt-6.250¶
     Joerger M, Schellens JHM.  Reply to the letter to the editor from Egorin. Clin Cancer Res 2008; 14 (8): 2517
     PubMed link

161. Impact Factor (2004): 23.858¶
     Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, Van De Vijver M, Berns A.  A Conditional Mouse Model for Malignant Mesothelioma.  Cancer Cell 2008; 13 (3): 261-271.
     PubMed link

162. Impact Factor (2004): 2.065¶
     Joosten J, Bertholet J, Keemers-Gels M, Barendregt W, Ruers T.  Pulmonary resection of colorectal metastases in patients with or without a history of hepatic metastases. Eur J Surg Oncol 2008; 34 (8): 895-899.
     PubMed link

163. Impact Factor (2004): 2.620¶
     Joosten K, Cohen SX, Emsley P, Mooij W, Lamzin VS, Perrakis A.  A knowledge-driven approach for crystallographic protein model completion. Acta Crystallogr D Biol Crystallogr 2008; 64 (4): 416-424.
     PubMed link

164. Impact Factor (2004): 7.672¶
     Jorritsma A, Bins AD, Schumacher TNM, Haanen JBAG.  Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. Cancer Res 2008; 68 (7): 2455-2462.
     PubMed link

165. Impact Factor (2004): 2.065¶
     Kaas R, Muller SH, Hart AA, Rutgers EJ.  Stage of breast cancers found during the surveillance of women with a familial or hereditary risk. Eur J Surg Oncol 2008; 34 501-507.
     PubMed link

166. Impact Factor (2004): 3.263¶
     Kalverda B, Roling MD, Fornerod M.  Chromatin organization in relation to the nuclear periphery. FEBS Lett 2008; 582 (14): 2017-2022.
     PubMed link

167. Impact Factor (2004): 5.581¶
     Kanters E, van Rijssel J, Hensbergen PJ, Hondius D, Mul FP, Deelder AM, Sonnenberg A, van Buul JD, Hordijk PL.  Filamin B mediates ICAM-1-driven leukocyte transendothelial migration. J Biol Chem 2008; 283 31830-31839.
     PubMed link

168. Impact Factor (2004): 3.455¶
     Kappers I, Belderbos JS, Burgers JA, Van Zandwijk N, Groen HJ, Klomp HM.  Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients. Lung Cancer 2008; 59 385-390.
     PubMed link

169. Impact Factor (2004): 15.484¶
     Kappers I, Klomp HM, Burgers JA, Van Zandwijk N, Haas RL, van Pel R.  Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol 2008; 26 (25): 4205-4207.
      PM:18757336">PubMed link

170. Impact Factor (2004): 0.559¶
     Karim RB, de Lint CA, van Galen SR, van Rozelaar L, Nieuwkerk PT, Askarizadeh E, Hage JJ.  Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients. Aesthetic Plast Surg 2008; 32 (6): 873-878.
     PubMed link

171. Impact Factor (2004): 1.299¶
     Kartachova MS, Valdes Olmos RA, Haas RL, Hoebers FJ, Herk M, Verheij M.  99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl Med Commun 2008; 29 (1): 39-44.
     PubMed link

172. Impact Factor (2004): 3.314¶
     Kedde M, Agami R.  Interplay between microRNAs and RNA-binding proteins determines developmental processes. Cell Cycle 2008; 7 (7): 899-903.
     PubMed link

173. Impact Factor (2004): 19.266¶
     Keller AM, Schildknecht A, Xiao Y, van den Broek M, Borst J.  Expression of Costimulatory Ligand CD70 on Steady-State Dendritic Cells Breaks CD8(+) T Cell Tolerance and Permits Effective Immunity. Immunity 2008; 29 (6): 934-946.
     PubMed link

174. Impact Factor (2004): -¶
     Kerkhoven RM, Sie D, Nieuwland M, Heimerikx M, De Ronde J, Brugman W, Velds A.  The T7-primer is a source of experimental bias and introduces variability between microarray platforms. PLoS ONE 2008; 3 (4): e1980
     PubMed link

175. Impact Factor (2004): 6.954¶
     Klijn C, Holstege H, Ridder JD, Liu X, Reinders M, Jonkers J, Wessels L.  Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res 2008; 36 (2): e13 (16pp)
     PubMed link

176. Impact Factor (2004): 5.039¶
     Knijnenburg TA, Wessels LF, Reinders MJ.  Combinatorial influence of environmental parameters on transcription factor activity. Bioinformatics 2008; 24 (13): i172-i181
     PubMed link

177. Impact Factor (2004): -¶
     Knijnenburg TA, Wessels LFA, Reinders MJT.  Creating gene set activity profiles with time-series expression data. Int J Bioinform Res Appl 2008; 4 (3): 306-323.
     PubMed link

178. Impact Factor (2004): 13.156¶
     Knipscheer P, Flotho A, Klug H, Olsen JV, van Dijk WJ, Fish A, Johnson ES, Mann M, Sixma TK, Pichler A.  Ubc9 sumoylation regulates SUMO target discrimination.  Mol Cell 2008; 31 (3): 371-382.
     PubMed link

179. Impact Factor (2004): 3.314¶
     Knoops L, de Jong D.  The role of the p53 pathway in the treatment of follicular lymphoma. Cell Cycle 2008; 7 (4): 436-439.
     PubMed link

180. Impact Factor (2004): 3.917¶
     Kootstra J, Hoekstra-Weebers JE, Rietman H, de Vries J, Baas P, Geertzen JH, Hoekstra HJ.  Quality of Life After Sentinel Lymph Node Biopsy or Axillary Lymph Node Dissection in Stage I/II Breast Cancer Patients: A Prospective Longitudinal Study. Ann Surg Oncol 2008; 15 (9): 2533-2541.
     PubMed link

181. Impact Factor (2004): 9.336¶
     Koppers-Lalic D, Verweij MC, Lipinska AD, Wang Y, Quinten E, Reits EA, Koch J, Loch S, Rezende MM, Daus F, Bienkowska-Szewczyk K, Osterrieder N, Mettenleiter TC, Heemskerk MH, Tampe R, Neefjes JJ, Chowdhury SI, Ressing ME, Rijsewijk FA, Wiertz EJ.  Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP. PLoS Pathog 2008; 4 (5): e1000080
     PubMed link

182. Impact Factor (2004): IP-2.295¶
     Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG.  Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors. Neuroendocrinology 2008; Oct 7. [Epub ahead of print] in press
     PubMed link

183. Impact Factor (2004): 5.581¶
     Kortlever RM, Nijwening JH, Bernards R.  TGFbeta requires its target plasminogen activator inhibitor-1 for cytostatic activity. J Biol Chem 2008; 283 (36): 24308-23313.
     PubMed link

184. Impact Factor (2004): 4.317¶
     Kortlever RM, Brummelkamp TR, Van Meeteren LA, Moolenaar WH, Bernards R.  Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Mol Cancer Res 2008; 6 (9): 1452-1460.
     PubMed link

185. Impact Factor (2004): 4.800¶
     Kraus M, Malenke E, Gogel J, Muller H, Ruckrich T, Overkleeft H, Ovaa H, Koscielniak E, Hartmann JT, Driessen C.  Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther 2008; 7 (7): 1940-1948.
     PubMed link

186. Impact Factor (2004): 4.290¶
     Kreike B, Hart AAM, van de Velde T, Borger J, Peterse H, Rutgers E, Bartelink H, van de Vijver MJ.  Continuing Risk of Ipsilateral Breast Relapse After Breast-Conserving Therapy at Long-Term Follow-up. Int J Radiat Oncol Biol Phys 2008; 71 (4): 1014-1021.
     PubMed link

187. Impact Factor (2004): -¶
     Kreukels BPC, van Dam FSAM.  Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer 2008; 8 80-87.
     PubMed link

188. Impact Factor (2004): 2.468¶
     Kreukels BPC, Hamburger HL, de Ruiter MB, van Dam FSAM, Ridderinkhof KR, Boogerd W, Schagen SB.   ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol 2008; 119 533-541.
     PubMed link

189. Impact Factor (2004): geen¶
     Kroon BB, Hoefnagel CA, Valdes Olmos RA, Nieweg OE.  [Regional lymph nodes at a distance]
     Regionale lymfekliergebieden op afstand. Ned Tijdschr Geneeskd 2008; 152 (37): 1997-2000.
     PubMed link

190. Impact Factor (2004): -¶
     Kroon BBR, Noorda EM, Vrouenraets BC, van Slooten GW, Nieweg OE.  Isolated limb perfusion for melanoma. Surg Oncol Clin N Am 2008; 17 (4): 785-94, viii.
     PubMed link

191. Impact Factor (2004): 2.751¶
     Kroon BK, Leijte JA, van Boven H, Wessels LF, Velds A, Horenblas S, van't Veer LJ.  Microarray gene-expression profiling to predict lymph node metastasis in penile carcinoma. BJU Int 2008; 102 (4): 510-515.
     PubMed link

192. Impact Factor (2004): 4.121¶
     Kuijl C, Tuin AW, Overkleeft H, Neefjes J.  Reciprocal chemical genetics for swift lead and target identification. Mol Biosyst 2008; 4 (10): 1001-1008.
     PubMed link

193. Impact Factor (2004): 29.887¶
     Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS.  Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133 (6): 1019-1031.
     PubMed link

194. Impact Factor (2004): 1.561¶
     Kunkler IH, Canney P, van Tienhoven G, Russell NS, MRC/EORTC (BIG 2-04) SUPREMO Trial Management Group.  Elucidating the Role of Chest Wall Irradiation in 'Intermediate-risk' Breast Cancer: the MRC/EORTC SUPREMO Trial. Clin Oncol 2008; 20 (1): 31-34.
     PubMed link

195. Impact Factor (2004): 4.635¶
     Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ.  UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99 (2): 275-282.
     PubMed link

196. Impact Factor (2004): 4.635¶
     Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, Punt CJ, Guchelaar HJ.  GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 2008;  99 (8): 1316-1321.
     PubMed link

197. Impact Factor (2004): 4.390¶
     Lagas JS, Sparidans RW, van Waterschoot RA, Wagenaar E, Beijnen JH, Schinkel AH.  P-glycoprotein limits oral availability, brain penetration and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrob Agents Chemother 2008; 52 (3): 1034-1039.
     PubMed link

198. Impact Factor (2004): 4.304¶
     Lange MM, Maas CP, Marijnen CA, Wiggers T, Rutten HJ, Kranenbarg EK, Van de Velde CJ.  Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg 2008; 95 (8): 1020-1028.
     PubMed link

199. Impact Factor (2004): 15.484¶
     Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ.  Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008; 26 (22): 3770-3776.
     PubMed link

200. Impact Factor (2004): -¶
     Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR.  Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer 2008; 9 (2): 85-91.
     PubMed link

201. Impact Factor (2004): 5.529¶
     Langerak P, Krijger PH, Heideman MR, van den Berk PC, Jacobs H.  Somatic hypermutation of immunoglobulin genes: lessons from proliferating cell nuclear antigenK164R mutant mice. Philos Trans R Soc Lond B Biol Sci 2008; Nov 13. [Epub ahead of print] in press
     PubMed link

202. Impact Factor (2004): 6.250¶
     Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, West RB, Gilks CB, Van De Rijn M.  Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008; 14 (5): 1423-1430.
     PubMed link

203. Impact Factor (2004): IP-2.217¶
     Leijte JA, Horenblas S.  Shortcomings of the current TNM classification for penile carcinoma: time for a change? World J Urol 2008; Aug 9. [Epub ahead of print] in press
     PubMed link

204. Impact Factor (2004): 5.634¶
     Leijte JA, Valdés Olmos RA, Nieweg OE, Horenblas S.  Anatomical Mapping of Lymphatic Drainage in Penile Carcinoma with SPECT-CT: Implications for the Extent of Inguinal Lymph Node Dissection. Eur Urol 2008; 54 (4): 885-892.
     PubMed link

205. Impact Factor (2004): 5.634¶
     Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S.  Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54 (1): 161-169.
     PubMed link

206. Impact Factor (2004): 4.053¶
     Leijte JA, Gallee M, Antonini N, Horenblas S.  Evaluation of Current TNM Classification of Penile Carcinoma. J Urol 2008; 180 (3): 933-938.
     PubMed link

207. Impact Factor (2004): 1.799¶
     Leijte JAP, Oddens JR, Lock TMTW.  Holmium laser lithotripsy for ureteral calculi: Predictive factors for complications and success. J Endourol 2008; 22 (2): 257-260.
     PubMed link

208. Impact Factor (2004): 3.455¶
     Li WW, Visser O, Ubbink DT, Klomp HM, Kloek JJ, de Mol BA.  The influence of provider characteristics on resection rates and survival in patients with localized non-small cell lung cancer. Lung Cancer 2008; 60 441-451.
     PubMed link

209. Impact Factor (2004): 3.503¶
     Linthorst Homan MW, de Korte J, Grootenhuis MA, Bos JD, Sprangers MA, van der Veen JP.  Impact of childhood vitiligo on adult life. Br J Dermatol 2008; 159 (4): 915-920.
     PubMed link

210. Impact Factor (2004): geen¶
     Littler DR, Harrop SJ, Brown LJ, Pankhurst GJ, Mynott AV, Luciani P, Mandyam RA, Mazzanti M, Tanda S, Berryman MA, Breit SN, Curmi PMG.  Comparison of vertebrate and invertebrate CLIC proteins: The crystal structures of Caenorhabditis elegans EXC-4 and Drosophila melanogaster DmCLIC. Proteins Struct Funct Genet 2008; 71 (1): 364-378.
     PubMed link

211. Impact Factor (2004): 2.470¶
     Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, Peeters MJ, Gilhuijs KG.  Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol 2008; 191 (5): 1331-1338.
     PubMed link

212. Impact Factor (2004): 2.074¶
     Loonen MP, Hage JJ, Kon M.  Plastic Surgery Classics: characteristics of 50 top-cited articles in four Plastic Surgery Journals since 1946. Plast Reconstr Surg 2008; 121 (5): 320e-327e.
     PubMed link

213. Impact Factor (2004): -¶
     Los AP, de Widt J, Van Blitterswijk WJ, Divecha N.  Is there a role for diacylglycerol kinase-zeta in cell cycle regulation? Adv Enzyme Regul 2008; 48 31-39.
     PubMed link

214. Impact Factor (2004): nvt-2.324¶
     Lukas A, van der Weide M, Boogerd W, Prevoo W, Zuurmond WW, Sanders M.  Adhesive Arachnoiditis Following Percutaneous Cervical Cordotomy-May We Still Use Lipiodol? J Pain Symptom Manage 2008; 36 (5): e1-e4
     PubMed link

215. Impact Factor (2004): 4.147¶
     Lyle KS, Raaijmakers JH, Bruinsma W, Bos JL, de Rooij J.  cAMP-induced Epac-Rap activation inhibits epithelial cell migration by modulating focal adhesion and leading edge dynamics. Cell Signal 2008; 20 (6): 1104-1116.
     PubMed link

216. Impact Factor (2004): -¶
     Manzone TA, Dam HQ, Intenzo CM, Sagar VV, Schneider CJ, Seshadri P.  Postoperative management of thyroid carcinoma. Surg Oncol Clin N Am 2008; 17 (1): 197-218.
     PubMed link

217. Impact Factor (2004): 4.800¶
     Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.  Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 2008; 7 (8): 2280-2287.
     PubMed link

218. Impact Factor (2004): 15.678¶
     Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE.  Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.  J Natl Cancer Inst 2008; 100 (24): 1771-1779.
     PubMed link

219. Impact Factor (2004): 13.444¶
     Margadant C, Frijns E, Wilhelmsen K, Sonnenberg A.  Regulation of hemidesmosome disassembly by growth factor receptors. Curr Opin Cell Biol 2008; 20 (5): 589-596.
     PubMed link

220. Impact Factor (2004): 4.088¶
     Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y.  Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 2008; 73 (5): 1474-1483.
     PubMed link

221. Impact Factor (2004): 4.074¶
     McDermott LN, Wendling M, Nijkamp J, Mans A, Sonke JJ, Mijnheer BJ, van Herk M.  3D in vivo dose verification of entire hypo-fractionated IMRT treatments using an EPID and cone-beam CT. Radiother Oncol 2008; 86 (1): 35-42.
     PubMed link

222. Impact Factor (2004): 4.635¶
     Meijer J, Ogink J, Roos E.  Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer 2008; 99 (9): 1493-1501.
     PubMed link

223. Impact Factor (2004): 7.672¶
     Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E.  The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res 2008; 68 (12): 4701-4708.
     PubMed link

224. Impact Factor (2004): 4.539¶
     Meijerman I, Beijnen JH, Schellens JHM.  Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 2008; 34 (6): 505-520.
     PubMed link

225. Impact Factor (2004): 2.384¶
     Meijnen P, Gilhuijs KG, Rutgers EJ.  The effect of margins on the clinical management of ductal carcinoma in situ of the breast. J Surg Oncol 2008; 98 (8): 579-584.
     PubMed link

226. Impact Factor (2004): 3.917¶
     Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ.  Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the Breast. Ann Surg Oncol 2008; 15 235-243.
     PubMed link

227. Impact Factor (2004): 4.635¶
     Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ.  Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008; 98 137-142.
     PubMed link

228. Impact Factor (2004): 4.304¶
     Meijnen P, Rutgers EJ.  Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast (Br J Surg 2008; 95: 547-554). Br J Surg 2008; 95 (10): 1305
     PubMed link

229. Impact Factor (2004): 3.493¶
     Meuleman W, Engwegen JYMN, Gast MCW, Beijnen JH, Reinders MJT, Wessels LFA.  Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data. BMC Bioinformatics 2008; 9 88 (11pp)
     PubMed link

230. Impact Factor (2004): 6.440¶
     Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS.  BRAF(E600) in benign and malignant human tumours. Oncogene 2008; 27 877-895.
     PubMed link

231. Impact Factor (2004): 4.829¶
     Michaloglou C, Soengas MS, Mooi WJ, Peeper DS.  Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". J Invest Dermatol 2008; 128 (6): 1582-1583.
     PubMed link

232. Impact Factor (2004): 0.528¶
     Mijnheer B.  STATE OF THE ART OF IN VIVO DOSIMETRY. Radiat Prot Dosimetry 2008; 131 (1): 117-122.
     PubMed link

233. Impact Factor (2004): 19.266¶
     Miyazaki M, Miyazaki K, Itoi M, Katoh Y, Guo Y, Kanno R, Katoh-Fukui Y, Honda H, Amagai T, van Lohuizen M, Kawamoto H, Kanno M.  Thymocyte Proliferation Induced by Pre-T Cell Receptor Signaling Is Maintained through Polycomb Gene Product Bmi-1-Mediated Cdkn2a Repression. Immunity 2008; 28 (2): 231-245.
     PubMed link

234. Impact Factor (2004): 10.150¶
     Molloy T, van 't Veer LJ.  Recent advances in metastasis research. Curr Opin Genet Dev 2008; 18 (1): 35-41.
     PubMed link

235. Impact Factor (2004): 4.453¶
     Molloy TJ, Bosma AJ, van't Veer LJ.  Towards an optimized platform for the detection, enrichment, and semi-quantitation circulating tumor cells. Breast Cancer Res Treat 2008; 112 (2): 297-307.
     PubMed link

236. Impact Factor (2004): 2.751¶
     Mols F, Aquarius AE, Essink-Bot ML, Aaronson NK, Kil PJ, van de Poll-Franse LV.  Does diabetes mellitus as a comorbid condition affect the health-related quality of life in prostate cancer survivors? Results of a population-based observational study. BJU Int 2008; 102 (11): 1594-1600.
     PubMed link

237. Impact Factor (2004): 0.765¶
     Mostert S, Sitaresmi MN, Gundy CM, Sutaryo, Veerman AJ.  Parental experiences of childhood leukemia treatment in Indonesia. J Pediatr Hematol Oncol 2008; 30 (10): 738-743.
     PubMed link

238. Impact Factor (2004): 3.917¶
     Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T.  Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial? Ann Surg Oncol 2008; 15 144-157.
     PubMed link

239. Impact Factor (2004): 7.672¶
     Nagel R, le Sage C, Diosdado B, van der Waal M, Vrielink JA, Bolijn A, Meijer GA, Agami R.  Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008; 68 (14): 5795-5802.
     PubMed link

240. Impact Factor (2004): 3.000¶
     Nieboer P, de Vries EG, Mulder NH, Rodenhuis S, Bontenbal M, van der Wall E, van Hoesel QG, Smit WM, Hupperets P, Voest EE, Nooij MA, Boezen HM, van der Graaf WT.  Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. Bone Marrow Transplant 2008; 42 (7): 475-481.
     PubMed link

241. Impact Factor (2004): 7.672¶
     Nierkens S, den Brok MH, Sutmuller RP, Grauer OM, Bennink E, Morgan ME, Figdor CG, Ruers TJ, Adema GJ.  In vivo colocalization of antigen and cytidyl guanosyl within dendritic cells is associated with the efficacy of cancer immunotherapy. Cancer Res 2008; 68 (13): 5390-5396.
     PubMed link

242. Impact Factor (2004): 4.053¶
     Nieuwenhuijzen JA, Meinhardt W, Horenblas S.  Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol 2008; 179 (5 Suppl): S35-S38
     PubMed link

243. Impact Factor (2004): 5.634¶
     Nieuwenhuijzen JA, de Vries RR, Bex A, van der Poel HG, Meinhardt W, Antonini N, Horenblas S.  Urinary Diversions after Cystectomy: The Association of Clinical Factors, Complications and Functional Results of Four Different Diversions. Eur Urol 2008; 53 834-844.
     PubMed link

244. Impact Factor (2004): nvt-3.917¶
     Nieweg OE.  The lymphatic anatomy of the breast and Its implications for sentinel lymph node biopsy: a human cadaver study [Comment]. Ann Surg Oncol 2008; 15 (8): 2347
     PubMed link

245. Impact Factor (2004): geen¶
     Nieweg OE, van der Ploeg IM, Estourgie SH, Tanis PJ, Olmos RA.  [A decade of sentinel lymph node biopsy for breast cancer: time for adaptations]
     Een decennium schildwachtklierbiopsie voor borstkanker; tijd voor aanpassingen. Ned Tijdschr Geneeskd 2008; 152 (13): 782
     PubMed link

246. Impact Factor (2004): 4.290¶
     Nijkamp J, Pos FJ, Nuver TT, Jong RD, Remeijer P, Sonke JJ, Lebesque JV.  Adaptive Radiotherapy for Prostate Cancer Using Kilovoltage Cone-Beam Computed Tomography: First Clinical Results. Int J Radiat Oncol Biol Phys 2008; 70 (1): 75-82.
     PubMed link

247. Impact Factor (2004): 2.074¶
     Nipshagen MD, Hage JJ, Beekman WH.  Use of 2-octyl-cyanoacrylate skin adhesive (Dermabond) for wound closure following reduction mammaplasty: a prospective, randomized intervention study. Plast Reconstr Surg 2008; 122 (1): 10-18.
     PubMed link

248. Impact Factor (2004): 4.454¶
     Nuyten DS, Hastie T, Chi JT, Chang HY, Vijver MJ.  Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. Eur J Cancer 2008; 44 (15): 2319-2329.
     PubMed link

249. Impact Factor (2004): 3.788¶
     Nuyten DSA, van de Vijver MJ.  Using Microarray Analysis as a Prognostic and Predictive Tool in Oncology: Focus on Breast Cancer and Normal Tissue Toxicity. Semin Radiat Oncol 2008; 18 (2): 105-114.
     PubMed link

250. Impact Factor (2004): 4.532¶
     Oldenburg RA, Kroeze-Jansema KH, Houwing-Duistermaat JJ, Bayley JP, Dambrot C, van Asperen CJ, van den Ouweland AM, Bakker B, van Beers EH, Nederlof PM, Vasen H, Hoogerbrugge N, Cornelisse CJ, Meijers-Heijboer H, Devilee P.  Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21-22 as a putative breast cancer susceptibility locus. Genes Chromosomes Cancer 2008; 47 (11): 947-956.
     PubMed link

251. Impact Factor (2004): 1.565¶
     Oomen LC, Sacher R, Brocks HH, Zwier JM, Brakenhoff GJ, Jalink K.  Immersion oil for high-resolution live-cell imaging at 37 degrees C: optical and physical characteristics. J Microsc 2008; 232 (2): 353-361.
     PubMed link

252. Impact Factor (2004): 2.065¶
     Oskam IM, Hoebers F, Balm AJM, van Coevorden F, Bais EM, Hart AM, Van Den Brekel MWM.  Neck management in medullary thyroid carcinoma. Eur J Surg Oncol 2008; 34 (1): 71-76.
     PubMed link

253. Impact Factor (2004): 3.446¶
     Ovaa H, van Leeuwen F.  Chemical Biology Approaches to Probe the Proteome. Chembiochem 2008; 9 (18): 2913-2919.
     PubMed link

254. Impact Factor (2004): 2.621¶
     Overbeek LI, Hoogerbrugge N, van Krieken JH, Nagengast FM, Ruers TJ, Ligtenberg MJ, Hermens RP.   Most Patients with Colorectal Tumors at Young Age Do Not Visit a Cancer Genetics Clinic. Dis Colon Rectum 2008; 51 (8): 1249-1254.
     PubMed link

255. Impact Factor (2004): 3.917¶
     Peeters CF, de Waal RM, Wobbes T, Ruers TJ.  Metastatic dormancy imposed by the primary tumor: does it exist in humans? Ann Surg Oncol 2008; 15 (11): 3308-3315.
     PubMed link

256. Impact Factor (2004): nvt-29.887¶
     Peric-Hupkes D, van Steensel B.  Linking cohesin to gene regulation [Comment].  Cell 2008; 132 (6): 925-928.
     PubMed link

257. Impact Factor (2004): -¶
     Perrakis A, Romier C.  Assembly of protein complexes by coexpression in prokaryotic and eukaryotic hosts: an overview. Methods Mol Biol 2008; 426 247-256.
     PubMed link

258. Impact Factor (2004): -¶
     Peters PJ, Pierson J.  Immunogold labeling of thawed cryosections. Methods Cell Biol 2008; 88 131-149.
     PubMed link

259. Impact Factor (2004): 3.357¶
     Piet AH, Hulshof MC, Pieters BR, Pos FJ, de Reijke TM, Koning CC.  Clinical Results of a Concomitant Boost Radiotherapy Technique for Muscle-Invasive Bladder Cancer
     Ergebnisse nach primarer perkutaner Radiotherapie mittels konkomitanter Boost-Technik nach transurethraler Resektion muskelinvasiver Harnblasenkarzinome.  Strahlenther Onkol 2008; 184 (6): 313-318.
     PubMed link

260. Impact Factor (2004): 4.635¶
     Pieterse AH, Baas-Thijssen MC, Marijnen CA, Stiggelbout AM.  Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration. Br J Cancer 2008; 99 (6): 875-882.
     PubMed link

261. Impact Factor (2004): 13.444¶
     Pietersen AM, van Lohuizen M.  Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol 2008; 20 (2): 201-207.
     PubMed link

262. Impact Factor (2004): 10.896¶
     Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, et al.   CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008; 111 (5): 2765-2775.
     PubMed link

263. Impact Factor (2004): 6.273¶
     Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FBL, Hoogerbrugge N, Spurdle AB, Tavtigian SV.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008; 29 (11): 1282-1291.
     PubMed link

264. Impact Factor (2004): -¶
     Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Hoogenraad W, Muller RP, Dubois JB, Bolla M, Van Der Hulst M, Warlam-Rodenhuis CC, Pierart M, Horiot JC.  The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. Cancer Radiother 2008; 12 (6-7): 565-570.
     PubMed link

265. Impact Factor (2004): 2.134¶
     Prevoo W, van den Bosch MA, Horenblas S.  Radiofrequency ablation for treatment of sporadic angiomyolipoma. Urology 2008; 72 (1): 188-191.
     PubMed link

266. Impact Factor (2004): geen¶
     Prevoo W, van den Bosch MA, Horenblas S.  [Guideline 'Renal cell carcinoma']
     Richtlijn 'Niercelcarcinoom'. Ned Tijdschr Geneeskd 2008; 152 (23): 1350
     PubMed link

267. Impact Factor (2004): 13.444¶
     Prieur A, Peeper DS.  Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008; 20 (2): 150-155.
     PubMed link

268. Impact Factor (2004): 25.556¶
     Puschendorf M, Terranova R, Boutsma E, Mao X, Isono KI, Brykczynska U, Kolb C, Otte AP, Koseki H, Orkin SH, van Lohuizen M, Peters AHFM.  PRC1 and Suv39h specify parental asymmetry at constitutive heterochromatin in early mouse embryos. Nat Genet 2008; 40 (4): 411-420.
     PubMed link

269. Impact Factor (2004): 2.611¶
     Quaak SG, van den Berg JH, Toebes M, Schumacher TNM, Haanen JBAG, Beijnen JH, Nuijen B.  GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. Eur J Pharm Biopharm 2008; 70 (2): 429-438.
     PubMed link

270. Impact Factor (2004): 9.425¶
     Raijmakers R, Berkers CR, de Jong A, Ovaa H, Heck AJ, Mohammed S.  Automated online sequential isotope labeling for protein quantitation applied to proteasome tissue-specific diversity. Mol Cell Proteomics 2008; 7 (9): 1755-1762.
     PubMed link

271. Impact Factor (2004): IP-3.354¶
     Repanas K, Fuentes G, Cohen SX, Bonvin AM, Perrakis A.  Insights into the DNA cleavage mechanism of human LINE-1 retrotransposon endonuclease. Proteins 2008; Sep 2. [Epub ahead of print] in press
     PubMed link

272. Impact Factor (2004): 0.597¶
     Retel VP, Hummel MJ, Van Harten WH.  Early phase Technology Assessment of nanotechnology in oncology. Tumori 2008; 94 (2): 284-290.
     PubMed link

273. Impact Factor (2004): 4.371¶
     Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LFA.  A comprehensive analysis of prognostic signatures reveals the high predictive capacity of Proliferation, Immune response and RNA splicing modules in breast cancer. Breast Cancer Research 2008; 10 R93
     PubMed link

274. Impact Factor (2004): 0.597¶
     Riegman PHJ, Llombart Bosch A, Dinjens WNM, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, et al.   OECI TuBaFrost tumor biobanking. Tumori 2008; 94 (2): 160-163.
     PubMed link

275. Impact Factor (2004): 0.597¶
     Ringborg U, de Valeriola D, van Harten W, Bosch AL, Lombardo C, Nilsson K, Philip T, Pierotti MA, Riegman P, Saghatchian M, Storme G, Tursz T, Verellen D.  Improvement of European translational cancer research. Collaboration between comprehensive cancer centers. Tumori 2008; 94 (2): 143-146.
     PubMed link

276. Impact Factor (2004): -¶
     Rit S, Wolthaus J, van Herk M, Sonke JJ.  On-the-fly motion-compensated cone-beam CT using an a priori motion model. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv 2008; 11 (Pt 1): 729-736.
     PubMed link

277. Impact Factor (2004): 8.662¶
     Rocha N, Neefjes J.  MHC class II molecules on the move for successful antigen presentation. EMBO J 2008; 27 (1): 1-5.
     PubMed link

278. Impact Factor (2004): -¶
     Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH.  Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 2006; 1 (1): 109-118.
     PubMed link

279. Impact Factor (2004): 6.435¶
     Rottenberg S, Jonkers J.  Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist Updat 2008; 11 51-60.
     PubMed link

280. Impact Factor (2004): 9.598¶
     Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105 (44): 17079-17084.
     PubMed link

281. Impact Factor (2004): 15.484¶
     Rutgers EJT.  Sentinel node biopsy: Interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. J Clin Oncol 2008; 26 (5): 698-702.
     PubMed link

282. Impact Factor (2004): nvt-15.516¶
     Rutgers EJT, Pusztai L, Bernards R.  Are short-term or long-term recurrence rates more important in breast cancer screening? Ann Intern Med 2008; 149 (5): 357
     PubMed link

283. Impact Factor (2004): 12.247¶
     Rutten HJ, den Dulk M, Lemmens VE, Van de Velde CJ, Marijnen CA.  Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 2008; 9 (5): 494-501.
     PubMed link

284. Impact Factor (2004): 6.383¶
     Rygiel TP, Mertens AE, Strumane K, van der Kammen R, Collard JG.  The Rac activator Tiam1 prevents keratinocyte apoptosis by controlling ROS-mediated ERK phosphorylation. J Cell Sci 2008; 121 (8): 1183-1192.
     PubMed link

285. Impact Factor (2004): 0.597¶
     Saghatchian M, Hummel H, Otter R, de Valeriola D, van Harten W, Paradiso A, Koot B, Ringborg U, Tursz T.  Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OECI).  Tumori 2008; 94 (2): 164-171.
     PubMed link

286. Impact Factor (2004): 4.555¶
     Santegoets LA, Van Seters M, Heijmans-Antonissen C, Kleinjan A, van Beurden M, Ewing PC, Kuhne LC, Beckmann I, Burger CW, Helmerhorst TJ, Blok LJ.  Reduced local immunity in HPV-related VIN: expression of chemokines and involvement of immunocompetent cells. Int J Cancer 2008; 123 (3): 616-622.
     PubMed link

287. Impact Factor (2004): 26.382¶
     Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, Eyüpoglu IY.  Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 2008; 14 (6): 629-632.
     PubMed link

288. Impact Factor (2004): 4.453¶
     Schaapveld M, Visser O, Louwman WJ, Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE.  The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 2008; 110 189-197.
     PubMed link

289. Impact Factor (2004): IP-2.589¶
     Schagen SB, Das E, Van Dam FS.  The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psychooncology 2008; Nov 19. [Epub ahead of print] in press
     PubMed link

290. Impact Factor (2004): 2.274¶
     Schagen SB, Boogerd W, Muller MJ, Huinink WT, Moonen L, Meinhardt W, Van Dam FS.  Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 2008; 47 63-70.
     PubMed link

291. Impact Factor (2004): 5.915¶
     Scheer MG, Stollman TH, Vogel WV, Boerman OC, Oyen WJ, Ruers TJ.  Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med 2008; 49 (6): 887-891.
     PubMed link

292. Impact Factor (2004): 4.454¶
     Scheer MG, Stollman TH, Boerman OC, Verrijp K, Sweep FC, Leenders WP, Ruers TJ, Oyen WJ.  Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Eur J Cancer 2008; (13):1835-40. Epub 2008 Jul 14. (13): 1835-1840.
     PubMed link

293. Impact Factor (2004): 2.681¶
     Schellens JHM, Grouls R, Guchelaar HJ, Touw DJ, Rongen GA, De Boer A, Van Bortel LM.  The Dutch model for clinical pharmacology: Collaboration between physician- and pharmacist-clinical pharmacologists. Br J Clin Pharmacol 2008; 66 (1): 146-147.
     PubMed link

294. Impact Factor (2004): 15.612¶
     Schepers K, Swart E, van Heijst JW, Gerlach C, Castrucci M, Sie D, Heimerikx M, Velds A, Kerkhoven RM, Arens R, Schumacher TN.  Dissecting T cell lineage relationships by cellular barcoding. J Exp Med 2008; 205 (10): 2309-2318.
     PubMed link

295. Impact Factor (2004): 2.274¶
     Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB.  Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2008; 1-10.
     PubMed link

296. Impact Factor (2004): geen¶
     Schilder CMT, Linn SC, van Dam FSAM, Schagen SB.  De invloed van hormonale therapie op het cognitief functioneren van patiënten met het mammacarcinoom. Ned Tijdschr Geneeskd 2008; 152 494-498.
      PM:18389880">PubMed link

297. Impact Factor (2004): 1.725¶
     Schiltz PM, Dillman RO, Korse CM, Cubellis JM, Lee GJ, de Gast GC.  Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells. Cancer Biother Radiopharm 2008; 23 (2): 214-221.
     PubMed link

298. Impact Factor (2004): 14.795¶
     Schlisio S, Kenchappa RS, Vredeveld LCW, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look AT, Meyerson M, Peeper DS, Carter BD, Kaelin J.  The kinesin KIF1B? acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008; 22 (7): 884-893.
     PubMed link

299. Impact Factor (2004): 3.728¶
     Schrama D, Voigt H, Eggert AO, Xiang R, Zhou H, Schumacher TNM, Andersen MH, Thor Straten P, Reisfeld RA, Becker JC.  Immunological tumor destruction in a murine melanoma model by targeted LT? independent of secondary lymphoid tissue. Cancer Immunol Immunother 2008; 57 (1): 85-95.
     PubMed link

300. Impact Factor (2004): 2.565¶
     Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Koller M, Petersen MA, Sprangers MAG.  The relationship between overall quality of life and its subdimensions was influenced by culture: analysis of an international database. J Clin Epidemiol 2008; 61 (8): 788-795.
     PubMed link

301. Impact Factor (2004): 2.626¶
     Seigers R, Schagen SB, Beerling W, Boogerd W, van Tellingen O, Van Dam FS, Koolhaas JM, Buwalda B.  Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008; 186 (2): 168-175.
     PubMed link

302. Impact Factor (2004): 3.760¶
     Shanmugham A, Ovaa H.  DUBs and disease: activity assays for inhibitor development. Curr Opin Drug Discov Devel 2008; 11 (5): 688-696.
     PubMed link

303. Impact Factor (2004): 4.635¶
     Siegel-Lakhai WS, Zandvliet AS, Huitema ADR, Tibben MM, Milano G, Girre V, ras V, King A, Richmond E, Wanders J, Beijnen JH, Schellens JHM.  A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Br J Cancer 2008; 98 (8): 1320-1326.
     PubMed link

304. Impact Factor (2004): 2.278¶
     Sigurdson AJ, Ha M, Hauptmann M, Bhatti P, Sram RJ, Beskid O, Tawn EJ, Whitehouse CA, Lindholm C, Nakano M, et al.   International study of factors affecting human chromosome translocations. Mutat Res Genet Toxicol Environ Mutagen 2008; 652 (2): 112-121.
     PubMed link

305. Impact Factor (2004): -¶
     Simkens L, Tol J, Koopman M, Mol L, Antonini N, Van Krieken H, Punt C.  Current questions in the treatment of advanced colorectal cancer: The CAIRO studies of the Dutch Colorectal Cancer Group. Clin Colorectal Cancer 2008; 7 (2): 105-109.
     PubMed link

306. Impact Factor (2004): 26.218¶
     Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, Okkenhaug K, Hagenbeek TJ, Spits H, Cantrell DA.  Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 2008; 9 (5): 513-521.
     PubMed link

307. Impact Factor (2004): 2.065¶
     Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA.  Appendiceal neoplasms and pseudomyxoma peritonei: A population based study. Eur J Surg Oncol 2008; 34 196-201.
     PubMed link

308. Impact Factor (2004): 1.522¶
     Smeenk RM, Bruin SC, van Velthuysen MLF, Verwaal VJ.  In Brief. Curr Probl Surg 2008; 45 (8): 522-525.
     PubMed link

309. Impact Factor (2004): 1.522¶
     Smeenk RM, Bruin SC, van Velthuysen MLF, Verwaal VJ.  Pseudomyxoma Peritonei. Curr Probl Surg 2008; 45 (8): 527-575.
     PubMed link

310. Impact Factor (2004): 1.414¶
     Smit LH, Nieweg OE, Mooi WJ, Bonfrer JMG, Haanen JBAG, Kroon BBR, de Gast GC.  Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma. Anticancer Res 2008; 28 (4C): 2297-2302.
     PubMed link

311. Impact Factor (2004): 23.858¶
     Smit MA, Peeper DS.  Deregulating EMT and senescence: double impact by a single twist. Cancer Cell 2008; 14 (1): 5-7.
     PubMed link

312. Impact Factor (2004): 4.290¶
     Smitsmans MH, Pos FJ, de Bois J, Heemsbergen WD, Sonke JJ, Lebesque JV, van Herk M.  The influence of a dietary protocol on cone beam CT-guided radiotherapy for prostate cancer patients. Int J Radiat Oncol Biol Phys 2008; 71 (4): 1279-1286.
     PubMed link

313. Impact Factor (2004): 1.548¶
     Sonke GS, Beerepoot LV, Los M.  A patient with subdiaphragmatic air. Neth J Med 2008; 66 (2): 89-90.
     PubMed link

314. Impact Factor (2004): 6.750¶
     Sonke GS, Ludwig I, van Oosten H, Baars JW, Meijer E, Kater AP, de Jong D.  Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. Clin Infect Dis 2008; 47 (1): 105-108.
     PubMed link

315. Impact Factor (2004): 4.290¶
     Sonke JJ, Lebesque J, van Herk M.  Variability of Four-Dimensional Computed Tomography Patient Models. Int J Radiat Oncol Biol Phys 2008; 70 590-598.
     PubMed link

316. Impact Factor (2004): 1.801¶
     Soolsma J, Van Den Brekel MWM, Ackerstaff AH, Balm AJM, Tan B, Hilgers FJM.  Long-term results of Provox ActiValve, solving the problem of frequent candida- and "underpressure"-related voice prosthesis replacements. Laryngoscope  2008; 118 (2): 252-257.
     PubMed link

317. Impact Factor (2004): 2.935¶
     Sparidans RW, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH.  Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872 (1-2): 77-82.
     PubMed link

318. Impact Factor (2004): 4.635¶
     Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van de Vijver MJ, Seigneuric R, Buffa FM, Harris AL, Wouters BG, Lambin P.  Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 2008;  99 (11): 1884-1890.
     PubMed link

319. Impact Factor (2004): 4.074¶
     Steggerda MJ, van der Poel HG, Moonen LM.  An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors. Radiother Oncol 2008; 88 (1): 108-114.
     PubMed link

320. Impact Factor (2004): 7.672¶
     Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68 (15): 6084-6091.
     PubMed link

321. Impact Factor (2004): 4.555¶
     Stollman TH, Scheer MGW, Leenders WPJ, Verrijp KCN, Soede AC, Oyen WJG, Ruers TJM, Boerman OC.  Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer 2008; 122 (10): 2310-2314.
     PubMed link

322. Impact Factor (2004): 4.180¶
     Stortelers C, Kerkhoven R, Moolenaar WH.  Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics 2008; 9 387
     PubMed link

323. Impact Factor (2004): 2.561¶
     Strumane K, Song JY, Baas I, Collard JG.  Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency. Leuk Res  2008; 32 (1): 113-120.
     PubMed link

324. Impact Factor (2004): 1.339¶
     Stuiver MM, van Wilgen CP, de Boer EM, de Goede CJ, Koolstra M, van Opzeeland A, Venema P, Sterken MW, Vincent A, Dijkstra PU.  Impact of shoulder complaints after neck dissection on shoulder disability and quality of life. Otolaryngol Head Neck Surg 2008; 139 (1): 32-39.
     PubMed link

325. Impact Factor (2004): 1.644¶
     Swaneveld FH, van Vugt RM, de Boer JP, Dijkmans BA, Lems WF.  A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma. Clin Rheumatol 2008; 27 (2): 249-251.
      PM:17660934">PubMed link

326. Impact Factor (2004): 6.440¶
     Taghavi P, Verhoeven E, Jacobs JJ, Lambooij JP, Stortelers C, Tanger E, Moolenaar WH, van Lohuizen M.  In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene 2008; 27 (54): 6806-6816.
     PubMed link

327. Impact Factor (2004): 2.007¶
     Tanis PJ, Nieweg OE, Van Den Brekel MWM, Balm AJM.  Dilemma of clinically node-negative head and neck melanoma: Outcome of "watch and wait" policy, elective lymph node dissection, and sentinel node biopsy - A systematic review. Head Neck 2008; 30 (3): 380-389.
     PubMed link

328. Impact Factor (2004): 4.547¶
     ter Heine R, Scherpbier HJ, Crommentuyn KM, Bekker V, Beijnen JH, Kuijpers TW, Huitema AD.  A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008; 13 (6): 779-787.
     PubMed link

329. Impact Factor (2004): 4.632¶
     Terhaard CH, van der Schroeff MP, van Schie K, Eerenstein SE, Lubsen H, Kaanders JH, Smeele LE, Burlage FR, van den Ende PL, Baatenburg de Jong RJ.  The prognostic role of comorbidity in salivary gland carcinoma. Cancer 2008; 113 (7): 1572-1579.
     PubMed link

330. Impact Factor (2004): 0.623¶
     Terlou A, Hage JJ, van Beurden M.  Skinning clitorectomy and skin replacement in women with vulvar intra-epithelial neoplasia. J Plast Reconstr Aesthet Surg 2009; 62 (3): 341-345.
     PubMed link

331. Impact Factor (2004): 2.614¶
     Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, Abulafia O, Lucci JA, III, Begg AC.   Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 120 g/dL with erythropoietin vs above 100 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008; 108 317-325.
     PubMed link

332. Impact Factor (2004): 3.455¶
     Timmer-Bonte JN, Punt CJ, vd Heijden HF, van Die CE, Bussink J, Beijnen JH, Huitema AD, Tjan-Heijnen VC.  Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung Cancer 2008; 60 (2): 222-230.
     PubMed link

333. Impact Factor (2004): 2.392¶
     Timmers GJ, Kessels LW, Wilhelm AJ, Veldkamp AI, Bosch TM, Beijnen JH, Huijgens PC.  Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies. Ther Drug Monit 2008; 30 (3): 301-305.
     PubMed link

334. Impact Factor (2004): 4.003¶
     Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JAA, Foulkes WD.  Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: A multi-modal approach. Eur J Hum Genet 2008; 16 (7): 820-832.
     PubMed link

335. Impact Factor (2004): 4.875¶
     Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FLG, Vos AH, Mol L, Antonini NF, Punt CJA.  A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008; 19 (4): 734-738.
     PubMed link

336. Impact Factor (2004): 2.806¶
     Tol J, Cats A, Mol L, Koopman M, Bos MMEM, Van Der Hoeven JJM, Antonini NF, Van Krieken JHJM, Punt CJA.  Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 2008; 26 (4): 393-397.
     PubMed link

337. Impact Factor (2004): 4.290¶
     Topolnjak R, Vliet-Vroegindeweij C, Sonke JJ, Minkema D, Remeijer P, Nijkamp J, Elkhuizen P, Rasch C.  Breast-Conserving Therapy: Radiotherapy Margins for Breast Tumor Bed Boost. Int J Radiat Oncol Biol Phys 2008; 72 (3): 941-948.
     PubMed link

338. Impact Factor (2004): 6.068¶
     Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL.  Puromycin-sensitive aminopeptidase limits MHC class I presentation in dendritic cells but does not affect CD8 T cell responses during viral infections. J Immunol 2008; 180 (3): 1704-1712.
     PubMed link

339. Impact Factor (2004): 29.887¶
     Uren AG, Kool J, Matentzoglu K, de Ridder J, Mattison J, Van Uitert M, Lagcher W, Sie D, Tanger E, Cox T, Reinders M, Hubbard TJ, Rogers J, Jonkers J, Wessels L, Adams DJ, van Lohuizen M, Berns A.  Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 2008; 133 (4): 727-741.
     PubMed link

340. Impact Factor (2004): 2.971¶
     Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Schellens JHM, Beijnen JH.  Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin« given intravesically. Rapid Commun Mass Spectrom 2008; 22 (4): 462-470.
     PubMed link

341. Impact Factor (2004): 28.751¶
     van't Veer LJ, Bernards R.  Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452 (7187): 564-570.
     PubMed link

342. Impact Factor (2004): 23.858¶
     van Amerongen R, Berns A.  Targeted anticancer therapies: mouse models help uncover the mechanisms of tumor escape. Cancer Cell 2008; 13 (1): 5-7.
     PubMed link

343. Impact Factor (2004): 4.454¶
     van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, D'Haese S, Aaronson NK.  An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008; 44 (16): 2418-2424.
     PubMed link

344. Impact Factor (2004): 2.167¶
     van Beek S, De Jaeger K, Mijnheer B, Vliet-Vroegindeweij C.  Evaluation of a single-isocenter technique for axillary radiotherapy in breast cancer. Med Dosim 2008; 33 (3): 191-198.
     PubMed link

345. Impact Factor (2004): 4.868¶
     Van Blitterswijk WJ, Verheij M.  Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 2008; 14 (21): 2061-2074.
     PubMed link

346. Impact Factor (2004): 6.250¶
     van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD.  Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008; 14 (18): 5884-5892.
     PubMed link

347. Impact Factor (2004): 4.374¶
     van de Weerdt BCM, Littler DR, Klompmaker R, Huseinovic A, Fish A, Perrakis A, Medema RH.  Polo-box domains confer target specificity to the Polo-like kinase family. Biochim Biophys Acta Mol Cell Res 2008; 1783 (6): 1015-1022.
     PubMed link

348. Impact Factor (2004): 3.455¶
     van den Berg RM, Teertstra HJ, Van Zandwijk N, Van Tinteren H, Visser C, Pasic A, Sutedja TG, Baas P, Golding RP, Postmus PE, Smit EF.  CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer 2008; 60 57-61.
     PubMed link

349. Impact Factor (2004): 3.695¶
     van den Bout I, van Rheenen J, van Angelen AA, de Rooij J, Wilhelmsen K, Jalink K, Divecha N, Sonnenberg A.  Investigation into the mechanism regulating MRP localization. Exp Cell Res 2008; 314 (2): 330-341.
     PubMed link

350. Impact Factor (2004): 2.935¶
     van den Broek I, Sparidans RW, Schellens JH, Beijnen JH.  Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872 (1-2): 1-22.
     PubMed link

351. Impact Factor (2004): 2.971¶
     van den Broek I, Sparidans RW, Schellens JH, Beijnen JH.  Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. Rapid Commun Mass Spectrom 2008; 22 (18): 2915-2928.
     PubMed link

352. Impact Factor (2004): 7.490¶
     van den Heuvel M, Mandl R, Luigjes J, Hulshoff Pol H.  Microstructural organization of the cingulum tract and the level of default mode functional connectivity. J Neurosci 2008; 28 (43): 10844-10851.
     PubMed link

353. Impact Factor (2004): -¶
     van den Heuvel M, Lowik DW, van Hest JC.  Self-assembly and polymerization of diacetylene-containing peptide amphiphiles in aqueous solution. Biomacromolecules 2008; 9 (10): 2727-2734.
     PubMed link

354. Impact Factor (2004): 3.455¶
     van den Heuvel MM, Korse CM, Bonfrer JM, Baas P.  Non-invasive diagnosis of pleural malignancies: The role of tumour markers. Lung Cancer 2008; 59 350-354.
     PubMed link

355. Impact Factor (2004): 26.218¶
     van den Hoorn T, Neefjes J.  Activated pDCs: open to new antigen-presentation possibilities. Nat Immunol 2008; 9 (11): 1208-1210.
     PubMed link

356. Impact Factor (2004): 7.446¶
     van der Bogt KE, Vrancken Peeters MP, van Baalen JM, Hamming JF.  Resection of carotid body tumors: results of an evolving surgical technique. Ann Surg 2008; 247 (5): 877-884.
     PubMed link

357. 
     van der Krogt GN, Ogink J, Ponsioen B, Jalink K.  A comparison of donor-acceptor pairs for genetically encoded FRET sensors: application to the Epac cAMP sensor as an example. PLoS ONE 2008; 3 (4):
     PubMed link

358. Impact Factor (2004): -¶
     van der Ploeg HP, Streppel KR, van der Beek AJ, van der Woude LH, Van Harten WH, Van Mechelen W.  Underlying mechanisms of improving physical activity behavior after rehabilitation. Int J Behav Med 2008; 15 (2): 101-108.
     PubMed link

359. Impact Factor (2004): 3.917¶
     van der Ploeg IM, Tanis PJ, Valdes Olmos RA, Kroon BB, Rutgers EJ, Nieweg OE.  Breast Cancer Patients with Extra-Axillary Sentinel Nodes Only may be Spared Axillary Lymph Node Dissection. Ann Surg Oncol 2008; 15 (11): 3239-3243.
     PubMed link

360. Impact Factor (2004): 1.778¶
     van der Ploeg IMC, Valdés Olmos RA, Kroon BBR, Nieweg OE.  The Hybrid SPECT/CT as an Additional Lymphatic Mapping Tool in Patients with Breast Cancer. World J Surg 2008; 32 (9): 1930-1934.
     PubMed link

361. Impact Factor (2004): 2.065¶
     van der Ploeg IMC, Nieweg OE, Van Rijk MC, Valdés Olmos RA, Kroon BBR.  Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008; 34 (12): 1277-1284.
     PubMed link

362. Impact Factor (2004): 3.917¶
     van der Ploeg IMC, Valdés Olmos RA, Kroon BBR, Nieweg OE.  Tumor-positive sentinel node biopsy of the groin in clinically node-negative melanoma patients: Superficial or superficial and deep lymph node dissection? Ann Surg Oncol 2008; 15 (5): 1485-1491.
     PubMed link

363. Impact Factor (2004): 3.917¶
     van der Ploeg IMC, Kroon BBR, Antonini N, Valde?s Olmos, Rutgers EJT, Nieweg OE.  Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration. Ann Surg Oncol 2008; 15 (4): 1025-1031.
     PubMed link

364. Impact Factor (2004): nvt-5.634¶
     van der Poel HG.  Editorial Comment on: Marked Gene Transcript Level Alterations Occur Early During Radical Prostatectomy. Eur Urol 2008; 53 344
     PubMed link

365. Impact Factor (2004): 2.384¶
     van der Poel HG, Moonen L, Horenblas S.  Sequential treatment for recurrent localized prostate cancer. J Surg Oncol 2008; 97 (5): 377-382.
     PubMed link

366. Impact Factor (2004): nvt-5.634¶
     van der Poel HG.  Editorial comment on: Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer. Eur Urol 2008; 53 561-562.
     PubMed link

367. Impact Factor (2004): 2.751¶
     van der Poel HG, de Blok W, Bex A, Meinhardt W, Horenblas S.  Peroperative transrectal ultrasonography-guided bladder neck dissection eases the learning of robot-assisted laparoscopic prostatectomy. BJU Int 2008; 102 (7): 849-852.
     PubMed link

368. Impact Factor (2004): 0.775¶
     Van Der Schoot SC, Vainchtein LD, Nuijen B, Gore A, Mirejovsky D, Lenaz L, Beijnen JH.  Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrin. Pharmazie 2008; 63 (11): 796-805.
     PubMed link

369. Impact Factor (2004): nvt-52.589¶
     Van Der Spek E, Sonke GS.  Cetuximab for colorectal cancer [5]. N Engl J Med 2008; 358 (11): 1196
     PubMed link

370. Impact Factor (2004): -¶
     van der Stoop P, Boutsma EA, Hulsman D, Noback S, Heimerikx M, Kerkhoven RM, Voncken JW, Wessels LF, van Lohuizen M.  Ubiquitin E3 ligase Ring1b/Rnf2 of polycomb repressive complex 1 contributes to stable maintenance of mouse embryonic stem cells.  PLoS ONE 2008; 3 (5): e2235
     PubMed link

371. Impact Factor (2004): 6.250¶
     van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, Bex A, de Gast G, Haanen JBAG, Boven E.  Sunitinib for treatment of advanced renal cell cancer: Primary tumor response. Clin Cancer Res 2008; 14 (8): 2431-2436.
     PubMed link

372. Impact Factor (2004): 4.635¶
     van der Veldt AAM, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJM, Haanen JBAG.  Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008; 99 (2): 259-265.
     PubMed link

373. Impact Factor (2004): 7.490¶
     Van der Zee CE, Kreft M, Beckers G, Kuipers A, Sonnenberg A.  Conditional deletion of the Itgb4 integrin gene in Schwann cells leads to delayed peripheral nerve regeneration. J Neurosci 2008; 28 (44): 11292-11303.
     PubMed link

374. Impact Factor (2004): 4.074¶
     van Elmpt W, Nijsten S, Mijnheer B, Dekker A, Lambin P.  The next step in patient-specific QA: 3D dose verification of conformal and intensity-modulated RT based on EPID dosimetry and Monte Carlo dose calculations. Radiother Oncol 2008; 86 86-92.
     PubMed link

375. Impact Factor (2004): 4.074¶
     van Elmpt W, McDermott L, Nijsten S, Wendling M, Lambin P, Mijnheer B.  A literature review of electronic portal imaging for radiotherapy dosimetry. Radiother Oncol 2008; 88 (3): 289-309.
     PubMed link

376. Impact Factor (2004): 4.074¶
     van Elmpt W, Ollers M, Velders M, Poels K, Mijnheer B, Ruysscher DD, Dekker A, Lambin P, Boersma L.  Transition from a simple to a more advanced dose calculation algorithm for radiotherapy of non-small cell lung cancer (NSCLC): Implications for clinical implementation in an individualized dose-escalation protocol. Radiother Oncol 2008; 88 (3): 326-334.
     PubMed link

377. Impact Factor (2004): 2.000¶
     van Gerven MAJ, Taal BG, Lucas PJF.  Dynamic Bayesian networks as prognostic models for clinical patient management. J Biomed Informatics 2008; 41 (4): 515-529.
     PubMed link

378. Impact Factor (2004): 1.229¶
     Van Hell EA, Kuks JB, Janet Raat AN, Van Lohuizen MT, Cohen-Schotanus J.  Instructiveness of feedback during clerkships: Influence of supervisor, observation and student initiative. Med Teach 2008; 1-6.
     PubMed link

379. Impact Factor (2004): 7.264¶
     van Leuken R, Clijsters L, Wolthuis R.  To cell cycle, swing the APC/C. Biochim Biophys Acta 2008; 1786 (1): 49-59.
     PubMed link

380. Impact Factor (2004): 3.314¶
     van Leuken RJ, Luna-Vargas MP, Sixma TK, Wolthuis RM, Medema RH.  Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B.  Cell Cycle 2008; 7 (17): 2710-2719.
     PubMed link

381. Impact Factor (2004): 3.398¶
     Van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar WH.  Anticancer activity of FTY720: Phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett 2008; 266 (2): 203-208.
     PubMed link

382. Impact Factor (2004): 3.917¶
     Van Sandick JW, Kappers I, Baas P, Haas RL, Klomp HM.  Surgical treatment in the management of malignant pleural mesothelioma: A single institution's experience. Ann Surg Oncol 2008; 15 (6): 1757-1764.
     PubMed link

383. Impact Factor (2004): 52.589¶
     Van Seters M, van Beurden M, Ten Kate FJW, Beckmann I, Ewing PC, Eijkemans MJC, Kagie MJ, Meijer CJM, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MPM, Helmerhorst TJM.  Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358 (14): 1465-1473.
     PubMed link

384. Impact Factor (2004): 7.672¶
     Van Seters M, Beckmann I, Heijmans-Antonissen C, van Beurden M, Ewing PC, Zijlstra FJ, Helmerhorst TJ, Kleinjan A.  Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia. Cancer Res 2008; 68 (16): 6617-6622.
     PubMed link

385. Impact Factor (2004): 1.597¶
     Van Slambrouck S, Hilkens J, Steelant WFA.  Ether lipid 1-O-octadecyl-2-O-methyl-3-glycero-phosphocholine inhibits cell-cell adhesion through translocation and clustering of E-cadherin and episialin in membrane microdomains. Oncol Rep 2008; 19 (1): 123-128.
     PubMed link

386. Impact Factor (2004): 10.896¶
     Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, Buijs-Gladdines J, Horstmann M, van Wering ER, Soulier J, Pieters R, Meijerink JP.  The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.  Blood 2008; 111 (9): 4668-4680.
     PubMed link

387. Impact Factor (2004): 4.180¶
     van Vliet MH, Reyal F, Horlings HM, van de Vijver MJ, Reinders MJ, Wessels LF.  Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics 2008; 9 375
     PubMed link

388. Impact Factor (2004): 4.088¶
     van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, Schinkel AH.  Midazolam metabolism in Cytochrome P450 3A knockout mice can be attributed to upregulated CYP2C enzymes. Mol Pharmacol 2008; 73 1029-1036.
     PubMed link

389. Impact Factor (2004): 6.420¶
     van Welsem T, Frederiks F, Verzijlbergen KF, Faber AW, Nelson ZW, Egan DA, Gottschling DE, van Leeuwen F.  Synthetic lethal screens identify gene silencing processes in yeast and implicate the acetylated amino terminus of Sir3 in recognition of the nucleosome core. Mol Cell Biol 2008; 28 (11): 3861-3872.
     PubMed link

390. 
     Van Zandwijk N, Jassem E, Bonfrer JM, Mooi WJ, Van Tinteren H.  Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol 1992; 19 (1 Suppl 2): 37-43.
     PubMed link

391. Impact Factor (2004): 4.875¶
     Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB.  Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008; 19 623-629.
     PubMed link

392. Impact Factor (2004): 4.876¶
     Veltkamp SA, Beijnen JH, Schellens JHM.  Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy. Oncologist 2008; 13 (3): 261-276.
     PubMed link

393. Impact Factor (2004): 6.250¶
     Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH.  Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 2008; 14 (11): 3477-3486.
     PubMed link

394. Impact Factor (2004): 6.250¶
     Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, van den Heuvel IJ, Beijnen JH, Voest EE, Schellens JH.  Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors. Clin Cancer Res 2008; 14 (22): 7535-7544.
     PubMed link

395. Impact Factor (2004): 4.800¶
     Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JH.  New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther 2008; 7 (8): 2415-2425.
     PubMed link

396. Impact Factor (2004): 3.907¶
     Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JH.  Extensive metabolism and hepatic accumulation of gemcitabine following multiple oral and intravenous administration in mice. Drug Metab Dispos 2008; 36 (8): 1608-1615.
     PubMed link

397. Impact Factor (2004): 6.440¶
     Verbrugge I, de Vries E, Tait SW, Wissink EH, Walczak H, Verheij M, Borst J.  Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 2008; 27 574-584.
     PubMed link

398. Impact Factor (2004): 2.893¶
     Verbrugghe P, Kujala P, Waelput W, Peters PJ, Cuvelier CA.  Clusterin in human gut-associated lymphoid tissue, tonsils, and adenoids: localization to M cells and follicular dendritic cells. Histochem Cell Biol 2008; 129 (3): 311-320.
     PubMed link

399. Impact Factor (2004): 4.241¶
     Verheij M.  Clinical biomarkers and imaging for radiotherapy-induced cell death. Cancer Metastasis Rev 2008; 27 (3): 471-480.
     PubMed link

400. Impact Factor (2004): 4.453¶
     Verkooijen HM, Koot VC, Fioretta G, van der Heiden M, Schipper ME, Rapiti E, Peeters PH, Peterse JL, Bouchardy C.  Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 2008; 107 389-395.
     PubMed link

401. Impact Factor (2004): 4.074¶
     Vermeulen C, Verwijs-Janssen M, Begg AC, Vens C.  Cell cycle phase dependent role of DNA polymerase ? in DNA repair and survival after ionizing radiation. Radiother Oncol 2008; 86 (3): 391-398.
     PubMed link

402. Impact Factor (2004): 2.335¶
     Verstege MI, Ten Kate FJ, Reinartz SM, van Drunen CM, Slors FJ, Bemelman WA, Vyth-Dreese FA, Te Velde AA.  Dendritic Cell Populations in Colon and Mesenteric Lymph Nodes of Patients With Crohn's Disease. J Histochem Cytochem 2008; 56 233-241.
     PubMed link

403. Impact Factor (2004): 3.377¶
     Verstrepen BE, Bins AD, Rollier CS, Mooij P, Koopman G, Sheppard NC, Sattentau Q, Wagner R, Wolf H, Schumacher TN, Heeney JL, Haanen JB.  Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine 2008; 26 (26): 3346-3351.
     PubMed link

404. Impact Factor (2004): 3.917¶
     Verwaal VJ, Bruin S, Boot H, van Slooten G, Van Tinteren H.  8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer. Ann Surg Oncol 2008; 15 (9): 2426-2432.
     PubMed link

405. Impact Factor (2004): 2.384¶
     Verwaal VJ, Kusamura S, Baratti D, Deraco M.  The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol 2008; 98 (4): 220-223.
     PubMed link

406. Impact Factor (2004): 2.426¶
     Vékony H, Raaphorst FM, Otte AP, van Lohuizen M, Leemans CR, Van Der Waal I, Bloemena E.  High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol 2008; 61 (6): 744-749.
     PubMed link

407. Impact Factor (2004): 4.290¶
     Videtic GM, Belderbos JS, Spring Kong FM, Kepka L, Martel MK, Jeremic B.  Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 2008; 72 (2): 327-334.
     PubMed link

408. Impact Factor (2004): -¶
     Vissers JH, Nicassio F, van Lohuizen M, Di Fiore PP, Citterio E.  The many faces of ubiquitinated histone H2A: insights from the DUBs. Cell Div 2008; 3 8 (14pp)
     PubMed link

409. Impact Factor (2004): 6.250¶
     Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, Van De Wetering K, Schinkel AH.  Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 2008; 14 (24): 8152-8160.
     PubMed link

410. Impact Factor (2004): 3.446¶
     Vliem MJ, Ponsioen B, Schwede F, Pannekoek WJ, Riedl J, Kooistra MR, Jalink K, Genieser HG, Bos JL, Rehmann H.  8-pCPT-2'-O-Me-cAMP-AM: An Improved Epac-Selective cAMP Analogue. Chembiochem 2008; 9 (13): 2052-2054.
     PubMed link

411. Impact Factor (2004): 6.420¶
     Vormer TL, Foijer F, Wielders CL, Te Riele H.  ANCHORAGE-INDEPENDENT GROWTH OF POCKET-PROTEIN-DEFICIENT MURINE FIBROBLASTS REQUIRES BYPASS OF G2 ARREST AND CAN BE ACCOMPLISHED BY EXPRESSION OF TBX2. Mol Cell Biol 2008; 28 (24): 7263-7273.
     PubMed link

412. Impact Factor (2004): 1.996¶
     Vos MR, Bomans PH, Frederik PM, Sommerdijk NA.  The development of a glove-box/Vitrobot combination: Air-water interface events visualized by cryo-TEM. Ultramicroscopy 2008; 108 (11): 1478-1483.
      PM:18691818">PubMed link

413. Impact Factor (2004): 2.361¶
     Voskuil DW, Vrieling A, Korse CM, Beijnen JH, Bonfrer JMG, van Doorn J, Kaas R, Russell NS, Rutgers EJ, van Leeuwen FE, van 't Veer LJ, Rookus MA.  Effects of lycopene on the Insulin-like Growth Factor (IGF) system in breast cancer survivors and women at high familial breast cancer risk. Nutr Cancer 2008; 60 (3): 342-353.
     PubMed link

414. Impact Factor (2004): 4.642¶
     Vrieling A, Rookus MA, Kampman E, Bonfrer JM, Bosma A, Cats A, van Doorn J, Korse CM, Witteman BJ, van Leeuwen FE, van't Veer LJ, Voskuil DW.  No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17 (10): 2585-2593.
     PubMed link

415. Impact Factor (2004): -¶
     Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F, Choy H, Gandara DR.   Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer. Clin Lung Cancer 2008; 9 (1): 9-15.
     PubMed link

416. Impact Factor (2004): 5.423¶
     Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, van de Vijver MJ, van't Veer LJ, Peterse JL.  Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216 (2): 141-150.
     PubMed link

417. Impact Factor (2004): 4.714¶
     Weinkove D, Bastiani M, Chessa TA, Joshi D, Hauth L, Cooke FT, Divecha N, Schuske K.  Overexpression of PPK-1, the Caenorhabditis elegans Type I PIP kinase, inhibits growth cone collapse in the developing nervous system and causes axonal degeneration in adults. Dev Biol 2008; 313 (1): 384-397.
     PubMed link

418. Impact Factor (2004): 3.033¶
     Wilson NS, Young LJ, Kupresanin F, Naik SH, Vremec D, Heath WR, Akira S, Shortman K, Boyle J, Maraskovsky E, Belz GT, Villadangos JA.  Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling. Immunol Cell Biol 2008; 86 (2): 200-205.
     PubMed link

419. Impact Factor (2004): 6.250¶
     Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, van't Veer LJ, Ramaswamy S.  Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008; 14 (10): 2988-2993.
     PubMed link

420. Impact Factor (2004): 3.198¶
     Wolthaus JW, Sonke JJ, van Herk M, Damen EMF.  Reconstruction of a time-averaged midposition CT scan for radiotherapy planning of lung cancer patients using deformable registration. Med Phys 2008; 35 (9): 3998-4011.
     PubMed link

421. Impact Factor (2004): 4.290¶
     Wolthaus JWH, Sonke JJ, van Herk M, Belderbos JSA, Rossi MMG, Lebesque JV, Damen EMF.  Comparison of Different Strategies to Use Four-Dimensional Computed Tomography in Treatment Planning for Lung Cancer Patients. Int J Radiat Oncol Biol Phys 2008; 70 (4): 1229-1238.
     PubMed link

422. Impact Factor (2004): 13.156¶
     Wolthuis R, Clay-Farrace L, Van Zon W, Yekezare M, Koop L, Ogink J, Medema R, Pines J.  Cdc20 and Cks direct the spindle checkpoint-independent destruction of cyclin A. Mol Cell 2008; 30 (3): 290-302.
     PubMed link

423. Impact Factor (2004): 7.672¶
     Wong DJ, Nuyten DSA, Regev A, Lin M, Adler AS, Segal E, van de Vijver MJ, Chang HY.  Revealing targeted therapy for human cancer by gene module maps. Cancer Res 2008; 68 (2): 369-378.
     PubMed link

424. Impact Factor (2004): 3.917¶
     Wouters MW, Wijnhoven BP, Karim-Kos HE, Blaauwgeers HG, Stassen LP, Steup WH, Tilanus HW, Tollenaar RA.  High-volume versus low-volume for esophageal resections for cancer: the essential role of case-mix adjustments based on clinical data.  Ann Surg Oncol 2008; 15 (1): 80-87.
     PubMed link

425. Impact Factor (2004): 1.600¶
     Wouters MW, van Geel AN, Menke-Pluijmers M, de Kanter AY, de Bruin HG, Verhoog L, Eggermont AM.   Should internal mammary chain (IMC) sentinel node biopsy be performed? Outcome in 90 consecutive non-biopsied patients with a positive IMC scintigraphy. Breast 2008; 17 152-158.
     PubMed link

426. Impact Factor (2004): 15.484¶
     Wouters MW, van Geel AN, Nieuwenhuis L, Van Tinteren H, Verhoef C, van Coevorden F, Klomp HM.  Outcome After Surgical Resections of Recurrent Chest Wall Sarcomas.  J Clin Oncol 2008; 26 (31): 5113-5118.
     PubMed link

427. Impact Factor (2004): 6.068¶
     Xiao Y, Peperzak V, Keller AM, Borst J.  CD27 instructs CD4+ T cells to provide help for the memory CD8+ T cell response after protein immunization. J Immunol 2008; 181 (2): 1071-1082.
     PubMed link

428. Impact Factor (2004): 3.398¶
     Xue SA, Bendle GM, Holler A, Stauss HJ.  Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2. Immunology 2008; 124 (3): 315-321.
     PubMed link

429. Impact Factor (2004): 4.145¶
     Zandvliet AS, Schellens JHM, Beijnen JH, Huitema ADR.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clin Pharmacokinet 2008; 47 (8): 487-513.
     PubMed link

430. Impact Factor (2004): 8.033¶
     Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JHM, Huitema ADR.  PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression. Clin Pharmacol Ther 2008; 83 829-839.
     PubMed link

431. Impact Factor (2004): nvt-15.678¶
     Zeleniuch-Jacquotte A, Gu Y, Bruning PF, Bonfrer JMG, Koenig KL, Arslan AA, Toniolo P, Shore RE.  Re: C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2008; 100 (6): 443-444.
     PubMed link

432. Impact Factor (2004): 2.357¶
     Zerp SF, Vink SR, Ruiter GA, Koolwijk P, Peters E, van der Luit AH, de Jong D, Budde M, Bartelink H, Van Blitterswijk WJ, Verheij M.  Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents. Anticancer Drugs 2008; 19 (1): 65-75.
     PubMed link

433. Impact Factor (2004): 2.562¶
     Zhang H, Langeslag M, Breukels V, Jenks BG, Roubos EW, Scheenen WJJM.  Calcium channel kinetics of melanotrope cells in Xenopus laevis depend on environmental stimulation. Gen Comp Endocrinol 2008; 156 (1): 104-112.
     PubMed link

434. Impact Factor (2004): 3.907¶
     Zimmermann C, Van De Wetering K, van de Steeg E, Wagenaar E, Vens C, Schinkel AH.  Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos 2008; 36 (4): 631-640.
     PubMed link

435. Impact Factor (2004): 29.887¶
     Zlotorynski E, Agami R.  A PASport to cellular proliferation. Cell 2008; 134 (2): 208-210.
     PubMed link

436. Impact Factor (2004): 4.074¶
     Zuur CL, Simis YJ, Verkaik RS, Schornagel JH, Balm AJ, Dreschler WA, Rasch CR.  Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol 2008; 89 (1): 38-43.
     PubMed link

437. Impact Factor (2004): 2.007¶
     Zuur JK, Muller SH, Vincent A, Sinaasappel M, de Jongh FH, Hilgers FJ.  Assessment of tracheal temperature and humidity in laryngectomized individuals and the influence of a heat and moisture exchanger on tracheal climate. Head Neck 2008; 30 (8): 1072-1082.
     PubMed link

438. Impact Factor (2004): 1.565¶
     Zwier JM, Oomen L, Brocks L, Jalink K, Brakenhoff GJ.  Quantitative image correction and calibration for confocal fluorescence microscopy using thin reference layers and SIPchart-based calibration procedures. J Microsc 2008; 231 (Pt 1): 59-69.
     PubMed link

Ph.D. DISSERTATIONS

1.     Bruggeman,S.W.M. Polycomb group genes in brain development and cancer : Ink4a/Arf and beyond  [dissertation]. University of Amsterdam; 2008.

2.     De Witte,M.A. Adoptive transfer of tumor- and minor antigen-specific T cell reactivity in mouse models  [dissertation]. University of Leiden; 2008.

3.     Duursma,A.M. Molecular dissection of Cdc6 and the miR-148 family; two stories with common themes  [dissertation]. Leiden University; 2008.

4.     Ekhart,C. Pharmacogenetics and pharmacokinetics in high-dose alkylating chemotherapy  [dissertation]. University Utrecht; 2008.

5.     Engelsma,D. Nuclear export signals: small domains with large impact  [dissertation]. University Leiden; 2008.

6.     Engwegen,J.Y.M.N. Clinical proteomics in colorectal and renal cell cancer  [dissertation]. Utrecht University; 2008.

7.     Epping,M.M.T. Functional genetic screens as tools to discover signaling pathways targeted by cancer drugs [Functioneel genetische screens als methode voor de ontdekking van signaleringsroutes waar anti-kanker middelen op aangrijpen]  [dissertation]. University Utrecht; 2008.

8.     Geiger,T.R. Oncogenic and metastatic functions of the neurotrophic receptor TRKB  [dissertation]. University of Amsterdam; 2008.

9.     Hannemann,J. Gene expression profiling in breast cancer: A link between biology and clinical decision making  [dissertation]. University of Amsterdam; 2008.

10.  Heemsbergen,W.D. Radiation treatment in prostate cancer - Balancing between tumor control and toxicity  [dissertation]. University of Amsterdam; 2008.

11.  Hendriksen,J.V.R.B. Intracellular routing of ß-catenin  [dissertation]. University Leiden; 2008.

12.  Hooning,M.J. Adverse effects of treatment in long-term survivors of breast cancer  [dissertation]. Free University; 2008.

13.  Jongmans,P. The intelligibility of tracheoesophageal speech : an analytic and rehabilitation study  [dissertation]. s.n.; 2008.

14.  Jorritsma-Smit,A. Immunotherapy of melanoma : towards clinical application  [dissertation]. University Leiden; 2008.

15.  Keller,A.M. The role of CD70/CD27 interactions at the dendritic cell/T cell interface  [dissertation]. University of Amsterdam; 2008.

16.  Kuijl C. Regulation of Endosomal and Phagosomal Transport  [dissertation]. Leiden University; 2008.

17.  Lai,C. Supervised classification and spatial dependency analysis in human cancer using high throughput data  [dissertation]. Delft University of Technology; 2008.

18.  Langerak,P. DNA damage tolerance: from error free UV-damage bypass to mutagenesis of immunoglobulin genes  [dissertation]. University of Amsterdam; 2008.

19.  Neijssen,J.J. The fate of intracellular peptides and MHC class I antigen presentation  [dissertation]. University Leiden; 2008.

20.  Rocha,N. Molecular basis for the control of motor-based transport of MHC class II compartments  [dissertation]. Leiden University; 2008.

21.  Vainchtein,L.D. Liquid chromatography - triple quadrupole mass spectrometry: the gold standard for quantitative bioanalysis of anti-cancer agents  [dissertation]. University Utrecht; 2008.

22.  van den Bout,J.I. Identification and functional analysis of genes regulated by ß1 and ß3 integrins  [dissertation]. University of Amsterdam; 2008.

23.  Veltkamp,S.A. Clinical pharmacological and translationl research on novel formulations of anticancer drugs  [dissertation]. University Utrecht; 2008.

24.  Vogel,M.J. Genomic mapping of heterochromatin components using DamID  [dissertation]. University of Amsterdam; 2008.

25.  Zuur,J.K. Postlaryngectomy pulmonary physiology and tracheal climate and the influence of a heat moisture exchanger (HME)  [dissertation]. University of Amsterdam; 2008.

Other publications

1.        Impact Factor (2004): geen¶
Aleman B, van der Maazen R.  Rol bestraling bij patiënten met Hodgkin-lymfoom. Tijdschr Kanker 2008; 32 (1): 12-15.

2.        Impact Factor (2004): nvt-4.074¶
Antonini N, Bartelink H.  Letter to the editor (letter - reply). Radiother Oncol 2008; 86 286

3.        Impact Factor (2004): geen¶
Bleeker MCG, Heideman DAM, Horenblas S, Snijders PJF, Meijer CJLM.  Peniskanker: van risicofactoren tot moleculaire pathogenese. Ned Tijdschr Oncol 2008; 5 (6): 243-251.

4.        Impact Factor (2004): geen¶
Boekhout A.  Cardiotoxiciteit bij trastuzumab. Oncologica 2008; 25 (2): 12-15.

5.        Impact Factor (2004): - nvt¶
Copper MP, Triesscheijn M, Tan IB, Ruevekamp MC, Stewart FA.  Response to Anderson and Stafford. Clin Otolaryngol 2008; 33 (2): 160

6.        Impact Factor (2004): -¶
Den Brok MWJ, Nuijen B, Beijnen JH.  Pharmaceutical development of intravenous preparations of the experimental cytostatic agents imexon and ES-285. Pharm Weekbl 2008; 143 (20): 112-117.

7.        Impact Factor (2004): 6.761¶
Doumont G, de Visser KE, Derksen PW, Jonkers J.  Models for angiogenesis: from fundamental mechanisms to anticancer treatment research. Drug Discov Today 2008; 4 75-82.

8.        Hilgers FJM, Van den Brekel M.  Cernea CR, editors.Pearls and pitfalls in head and neck surgery: practical tips to minimize complications. Basel: Karger,  2008; 5.3, Practical tips for voice rehabilitation after pharyngolaryngectomy. p. 96-7.

9.        Impact Factor (2004): geen¶
Hoebers FJP.  Prognostische factoren en voorspellende testen in de behandeling van hoofd-halskanker. Ned Tijdschr Oncol 2008; 5 (2): 83-86.

10.     Impact Factor (2004): geen¶
Hoekstra HJ, Nieweg OE.  Selectieve lymfadenectomie. Een fase III-multicenterstudie van klierdissectie versus observatie bij melanoom-patiënten met een positieve schildwachtklier. Ned Tijdschr Oncol 2008; 5 (8): 378-379.

11.     Impact Factor (2004): geen¶
Hooning MJ.  Late side effects of breast cancer treatment: a cohort study of patients from the Erasmus MC, Daniel den Hoed Cancer Center and the Netherlands Cancer Institute in Amsterdam. Daniel den Hoed Cancer News 2008; (1): 31-34.

12.     Impact Factor (2004): geen¶
Horenblas S.  RPLND bij vroege testistumoren. Tijdschr Kanker 2008; 32 (3): 20-23.

13.     Impact Factor (2004): nvt -¶
Horenblas S.  Editorial comment. Int Braz J Urol 2008; 34 (2): 189-190.

14.     Huisman C, Mallo H, van Riel C, Hulshoff A, van Steijn J. Immunotargeted therapie in de hemato- / oncologische zorg. Maarssen: Elsevier Gezondheidszorg; 2008; 336p.

15.     Impact Factor (2004): geen¶
Kerst JM, Pos FJ, Visser O, Horenblas S.  Nieuwe ontwikkelingen in de behandeling van spierinvasief blaascarcinoom. Ned Tijdschr Geneeskd 2008; 152 187-192.

16.     Impact Factor (2004): geen¶
Kerst M, Bergman A, Visser O, Pos F.  Adjuvante behandeling van het stadium 1 seminoma testis. Tijdschr Kanker 2008; 32 (3): 26-28.

17.     Impact Factor (2004): 12.247¶
Linn SC, Bueno-de-Mesquita JM, van de Vijver MJ.  Are gene signatures better than traditional clinical factors? – Authors' reply. Lancet Oncol 2008; 9 198-199.
http://dx.doi.org/10.1016/S1470-2045(08)70048-2

18.     Impact Factor (2004): geen¶
Mallo H.  De SIG immuno-/targeted therapy: laatste ontwikkelingen. Oncologica 2008; 25 (2): 11

19.     Impact Factor (2004): 2.507¶
Nawijn MC, Bergman AM, van der Poel HG.  Genetically engineered mouse models of prostate cancer. Eur Urol suppl 2008; 7 (8): 566-575.

20.     Impact Factor (2004): 2.615¶
Ovaa H, Leeuwenburgh MA, Overkleeft HS, Van der Marel GA, Van Boom J.  An expeditious route to the synthesis of highly functionalized chiral oxepines from monosaccharides. Tetrahedron Lett 1998; 39 (19): 3025-3028.

21.     Impact Factor (2004): geen¶
Sparidans JGM, van Leeuwen FE, De Bruin ML, Aleman BMP.  Mammacarcinoom na behandeling voor hodgkinlymfoom. Ned Tijdschr Oncol 2008; 5 (4): 144-149.

22.     Impact Factor (2004): 2.507¶
Steggerda MJ, van der Poel HG, Moonen LMF.  Predicting urinary morbidity after brachytherapy of localized prostate cancer. Eur Urol suppl 2008; 7 723-731.
-

23.     Van den Brekel M, Hilgers FJM.  Cernea CR, editors.Pearls and pitfalls in head and neck surgery: practical tips to minimize complications. Basel: Karger,  2008; 2.1, Preoperative workup of the neck in head and neck squamous cell carcinoma. p. 34-5.

24.     Impact Factor (2004): geen¶
van der Ploeg IMC, Straver ME, Rutgers EJT.  Aanvullende indicatie schildwachtklierbiopsie bij het mammacarcinoom? Ned Tijdschr Oncol 2008; 5 (2): 67-68.

25.     Impact Factor (2004): geen
geen¶
van Luttikhuizen A.  Ergotherapie en oncologie: Zitanalyse na abdominale perineale rectumextirpatie. Ned Tijdschr Ergother 2008; 36 (3): 24-29.

26.     Impact Factor (2004): geen¶
Verbruggen MB, Verheijen RHM, van de Goot FRW, van Beurden M, Dorsman JC.  Sereuze borderline-ovariumtumor in supradiafragmatische lymfklieren. Ned Tijdschr Oncol 2008; 5 (1): 27-32.

27.     Verheij M, van Blitterswijk W.  Kasis UN, Notario V, Haimowitz-Friedman A, Bar-Eli M, editors.Reviews in cancer biology & therapeutics. Kerala: Transworld Research Network,  2008;Sphingomyelin metabolism: Implications for cell signaling and drug uptake. p. 55-71.